US20120141583A1 - Alcohol resistant dosage forms - Google Patents

Alcohol resistant dosage forms Download PDF

Info

Publication number
US20120141583A1
US20120141583A1 US13/157,093 US201113157093A US2012141583A1 US 20120141583 A1 US20120141583 A1 US 20120141583A1 US 201113157093 A US201113157093 A US 201113157093A US 2012141583 A1 US2012141583 A1 US 2012141583A1
Authority
US
United States
Prior art keywords
dosage form
opioid
less
salt
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/157,093
Inventor
Richard O. Mannion
William H. McKenna
Edward P. O'Donnell
Helen Kathleen Danagher
Geoffrey Gerard Hayes
Hassan Mohammad
Derek Allan Prater
Harjit Tamber
Malcom Walden
Steve Whitelock
Wolfgang Fleischer
Udo Hahn
Christof Spitzley
Christian Leuner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Euroceltique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EPPCT/EP2005/050014 priority Critical
Priority to GB0403100A priority patent/GB0403100D0/en
Priority to GB0403100.1 priority
Priority to GBGB0501638.1A priority patent/GB0501638D0/en
Priority to GB0501638.1 priority
Priority to PCT/GB2005/050014 priority patent/WO2005079760A1/en
Priority to PCT/EP2006/000727 priority patent/WO2006079550A2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34889127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120141583(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US57477807A priority
Application filed by Euroceltique SA filed Critical Euroceltique SA
Priority to US13/157,093 priority patent/US20120141583A1/en
Publication of US20120141583A1 publication Critical patent/US20120141583A1/en
Assigned to PURDUE PHARMA L.P. reassignment PURDUE PHARMA L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EURO-CELTIQUE S.A.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29BPREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00Making granules
    • B29B9/02Making granules by dividing preformed material
    • B29B9/06Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00Use of polymers of unsaturated acids or derivatives thereof as moulding material B29K2035/00 takes precedence
    • B29K2033/04Polymers of esters
    • B29K2033/12Polymers of methacrylic acid esters, e.g. PMMA, i.e. polymethylmethacrylate
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0085Copolymers

Abstract

Opioid controlled release formulation resistant to alcohol extraction of the opioid.

Description

  • This application claims the benefit of GB patent application no. 0501638.1, filed on Jan. 28, 2005, of PCT patent application no. PCT/GB2005/050014 filed on Feb. 11, 2005, of U.S. provisional application No. 60/670,506, filed on Apr. 12, 2005 and of U.S. provisional application No. 60/730,339, filed on Oct. 26, 2005.
  • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to controlled release formulations resistant to alcohol extraction, in particular opioid controlled release formulations resistant to alcohol extraction.
  • BACKGROUND OF THE INVENTION
  • Pharmaceutical products are sometimes the subject of abuse. For example, a particular dose of opioid agonist may be more potent when administered parenterally as compared to the same dose administered orally. Some formulations can be tampered with to provide the opioid agonist contained therein for illicit use. Controlled release opioid agonist formulations are sometimes crushed, or subject to extraction with solvents (e.g., ethanol) by drug abusers to provide the opioid contained therein for immediate release upon oral or parenteral administration.
  • Controlled release opioid agonist dosage forms which can liberate a portion of the opioid upon exposure to ethanol, can also result in a patient receiving the dose more rapidly than intended if a patient disregards instructions for use and concomitantly uses alcohol with the dosage form.
  • Purdue Pharma L.P. currently markets sustained-release oxycodone in dosage forms containing 10, 20, 40 and 80 mg oxycodone hydrochloride under the tradename OxyContin.
  • U.S. Pat. Nos. 5,266,331; 5,508,042; 5,549,912 and 5,656,295 disclose sustained release oxycodone formulations.
  • Purdue Pharma L.P. is the NDA holder of sustained-release hydromorphone in dosage forms containing 12, 16, 24 and 32 mg hydromorphone hydrochloride under the tradename Palladone®.
  • During the development of Palladone®, in-vitro extraction and dissolution studies indicated that exposure of the formulation to ethanol increased the release of hydromorphone, as compared to release in water. Subsequent pharmacokinetic studies in healthy subjects have shown that the concomitant intake of ethanol with Palladone® Capsules can result in the rapid release and absorption of hydromorphone from the formulation.
  • U.S. Pat. Nos. 5,958,452; 5,965,161; 5,968,551; 6,294,195; 6,335,033; 6,706,281; and 6,743,442 disclose sustained release hydromorphone formulations.
  • U.S. Patent Publication Nos. 2003/0118641 and 2005/0163856 to Maloney et al. describe an opioid formulation which employs an ion exchange resin in conjunction with a hydrophobic matrix that is purportedly resistant to extraction of the opioid with commonly available solvents.
  • U.S Patent Publication No. 2004/0052731 to Hirsh et al. describes a pharmaceutical composition which can purportedly be used to reduce the likelihood of improper administration of drugs.
  • There continues to exist a need in the art for an oral dosage form comprising an opioid agonist with reduced opioid release upon exposure to alcohol.
  • All references cited herein, including the foregoing patents, patent applications and priority documents, are hereby incorporated by reference in their entireties.
  • OBJECTS AND SUMMARY OF THE INVENTION
  • It is an object of certain embodiments of the present invention to provide an oral controlled release dosage form comprising an opioid analgesic which is resistant to common extraction methods, in particular with ethanolic solutions, intended to liberate the opioid analgesic for illicit use.
  • It is an object of certain embodiments of the present invention to provide an oral controlled release dosage form comprising an opioid analgesic which is resistant to the release of the opioid analgesic when concomitantly used with alcohol.
  • It is an object of certain embodiments of the present invention to provide an oral controlled release dosage form comprising an opioid analgesic which has increased hardness and is resistant to crushing.
  • In certain embodiments, the present invention is directed to a controlled release dosage form comprising an opioid analgesic and a controlled release material; wherein the ratio of the amount of opioid analgesic released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of opioid analgesic released after 1 hour in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is 2:1 or less or less than about 2:1; 1.5:1 or less or less than about 1.5:1; or 1:1 or less or less than about 1:1. In certain such embodiments, the lower limit of this ratio is 0.5:1 or 1:1.
  • In certain embodiments, the present invention is directed to a controlled release dosage form comprising an opioid analgesic and a controlled release material; wherein the ratio of the amount of opioid analgesic released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 30% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of the opioid analgesic released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is 4:1 or less or less than about 4:1; 3:1 or less or less than about 3:1; or 2:1 or less or less than about 2:1. In certain such embodiments, the lower limit of this ratio is 0.5:1 or 1:1; or 1.7:1.
  • In certain embodiments, the present invention is directed to a controlled release dosage form comprising an opioid analgesic and a controlled release material; wherein the ratio of the amount of opioid analgesic released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 40% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of the opioid analgesic released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is 5:1 or less or less than about 5:1; 4:1 or less or less than about 4:1; or 3:1 or less or less than about 3:1. In certain such embodiments, the lower limit of this ratio is 0.5:1 or 1:1; or 2.6:1.
  • In certain embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of matrices comprising a therapeutically effective amount of hydromorphone or a pharmaceutically acceptable salt thereof, dispersed in a controlled release material; wherein the ratio of the amount of hydromorphone or a pharmaceutically acceptable salt thereof released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of hydromorphone or a pharmaceutically acceptable salt thereof released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is less than about 2:1. In more detail: In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of extruded matrices comprising a therapeutically effective amount of hydromorphone or a pharmaceutically acceptable salt thereof, dispersed in an alkylcellulose. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of extruded matrices comprising a therapeutically effective amount of hydromorphone or a pharmaceutically acceptable salt thereof, dispersed in an ethylcellulose. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of extruded matrices comprising a therapeutically effective amount of hydromorphone or a pharmaceutically acceptable salt thereof, dispersed in an alkylcellulose, the alkylcellulose being at least 50%, w/w of the matrices. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of extruded matrices consisting essentially of hydromorphone or a pharmaceutically acceptable salt thereof, dispersed in an alkylcellulose. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of extruded matrices consisting essentially of hydromorphone or a pharmaceutically acceptable salt thereof, dispersed in an alkylcellulose, an optional binder, and an optional plasticizer. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of extruded matrices comprising hydromorphone or a pharmaceutically acceptable salt thereof, dispersed in an alkylcellulose, wherein the matrices do not comprise an acrylic polymer.
  • In certain embodiments, the present invention is directed to a controlled release dosage form comprising a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material; wherein less than 25% of the opioid salt is released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.°. In more detail: In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of matrices comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a pharmaceutically acceptable excipient; and a layer comprising a controlled release material disposed about the matrix, e.g. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of matrices comprising a pharmaceutically acceptable salt of an opioid analgesic in a pharmaceutically acceptable excipient; and a layer comprising a controlled release material disposed about each of the matrices.
  • In certain embodiments the present invention is directed to the use of a sparingly water permeable thermoplastic polymer or a hydrophobic polymer as controlled release matrix material in the manufacture of an opioid controlled release matrix formulation to impart resistance to alcohol extraction of the opioid, wherein said formulation having the sparingly water permeable thermoplastic polymer or hydrophobic polymer as controlled release matrix material releases less opioid in an alcohol extraction test compared to the same formulation but with the sparingly water permeable thermoplastic polymer or hydrophobic polymer substituted entirely or partly by other matrix materials.
  • In certain embodiments the present invention is directed to the use of a sparingly water permeable thermoplastic polymer as controlled release matrix material in the manufacture of an opioid controlled release matrix formulation to impart resistance to alcohol extraction, wherein said formulation after 15 minutes shaking in 40% ethanol at room temperature using a Stuart Scientific Flask Shaker Model SF1 set at 500 to 600 oscillations per minute releases less than 35% of opioid. In certain such embodiments said formulation releases less than 30%, more preferred less than 25% of opioid salt, or from 15 to 25 opioid salt.
  • In certain embodiments the present invention is directed to the use of a hydrophobic material polymer as controlled release matrix material in the manufacture of an opioid controlled release matrix formulation to impart resistance to alcohol extraction, wherein less than 25% of the opioid is released after 1 hour of in-vitro dissolution of a dosage form comprising said formulation in 500 ml and/or 900 ml of Simulated Gastric Fluid with 20% ethanol using USP Apparatus I (basket) operating at 100 rpm at 37° C.
  • In certain embodiments the present invention is directed to the use of a hydrophobic material as controlled release matrix material in the manufacture of an opioid controlled release matrix formulation to impart resistance to alcohol extraction, wherein the ratio of the amount of opioid released after 1 hour of in-vitro dissolution of the dosage form comprising said formulation in 900 and/or 500 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37° C., to the amount of opioid released after 1 hour of in-vitro dissolution of the dosage form comprising said formulation in 900 and/or 500 ml of Simulated Gastric Fluid with 0% ethanol using an USP Apparatus I (basket) apparatus at 100 rpm at 37° C., is less than about 2:1.
  • In certain embodiments, the present invention is directed to a method of treating pain comprising administering to a patient in need thereof a dosage form as disclosed herein.
  • In certain embodiments, the present invention is directed to a method of deterring abuse of an opioid agonist comprising preparing a dosage form as disclosed herein.
  • The formulations disclosed herein are intended to release the drug over an extended period of time to provide a therapeutic effect. In certain embodiments, the controlled release formulations provide a at least a 12 hour or 24 hour therapeutic effect.
  • The term “controlled release” as it applies to an opioid agonist is defined for purposes of the present invention as the release of the opioid from the formulation at a rate which will provide a longer duration of action than a single dose of the normal (i.e., immediate release) formulation. For example, an immediate release oral formulation may release the drug over a 1-hour interval, compared to a controlled release oral formulation which may release the drug over a 4 to 24 hour interval.
  • For purposes of the present invention, the tell “opioid analgesic” is interchangeable with the term “opioid” and includes one agonist or a combination of more than one opioid agonist, and also includes the use of a mixed agonist-antagonist; a partial agonist and combinations of an opioid agonist and an opioid antagonist, wherein the combination provides an analgesic effect, stereoisomers thereof; an ether or ester thereof; or a mixture of any of the foregoing. With respect to certain embodiments of the present invention, the term “opioid agonist” is interchangeable with the term “opioid analgesic” and includes one agonist or a combination of more than one opioid agonist, and also includes the use of a mixed agonist-antagonist; a partial agonist; stereoisomers thereof; an ether or ester thereof; or a mixture of any of the foregoing.
  • The present invention disclosed herein is meant to encompass the use of any pharmaceutically acceptable salt of the opioid. The term “opioid salt” refers to a pharmaceutically acceptable salt of the opioid. Any embodiment of the invention referring to opioid is also meant to refer to opioid salt.
  • Pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, secium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate and the like; organic acid salts such as formate, acetate, trifluoroacetate, maleate, tartrate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate, and the like; amino acid salts such as arginate, asparginate, glutamate and the like.
  • The opioids used according to the present invention may contain one or more asymmetric centers and may give rise to enantiomers, diastereomers, or other stereoisomeric forms. The present invention is also meant to encompass the use of all such possible forms as well as their racemic and resolved forms and mixtures thereof. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, it is intended to include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.
  • In certain embodiments, the matrix or plurality of matrices of the dosage form disclosed herein consist essentially of an opioid analgesic dispersed in an alkylcellulose; an optional binder, and an optional plasticizer.
  • In certain embodiments, the dosage form as disclosed herein does not comprise an acrylic polymer. In certain embodiments, the matrix or plurality of matrices of the dosage form disclosed herein do not comprise an acrylic polymer.
  • As used herein, the term “stereoisomers” is a general term for all isomers of individual molecules that differ only in the orientation of their atoms is space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
  • The term “chiral center” refers to a carbon atom to which four different groups are attached.
  • The term “enantiomer” or “enantiomeric” refers to a molecule that is nonsuperimposeable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image rotates the plane of polarized light in the opposite direction.
  • The term “racemic” refers to a mixture of equal parts of enantiomers and which is optically inactive.
  • The term “resolution” refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.
  • The term “layer” means a material disposed about a substrate (which can include itself and one or more optional intermediate layers such e.g., a seal coat), which can be applied, e.g., as a coating. Layering of substrates can be performed by procedures known in the art including, e.g., spray coating, dipping or enrobing.
  • The term “disposed about” means that the layer material disposed about the particle covers at least a portion of the particle, with or without an intermediate layer or layers between the substance and the particle. In certain embodiments, the material covers an average of at least 50% of the surface area of the particle. In certain other embodiments, the material completely covers the particle.
  • The term “resistance to alcohol extraction” in the broadest sense refers to the ability of a formulation to release less opioid when subjected to a solution comprising ethanol than a comparative formulation, notwithstanding the fact that “resistance to alcohol extraction” can be alternatively or further defined with respect to specific embodiments of the invention. Within the meaning of the present invention resistance to alcohol extraction can be tested and defined by various “alcohol extraction tests” which involve subjecting the formulation to a solution comprising ethanol as described herein.
  • The term “controlled release matrix formulation” refers to the composition including the controlled release materials and the opioid. Unless specifically indicated the term “controlled release matrix formulation” refers to said formulation in intact form.
  • The term “controlled release dosage form” refers to the administration form comprising the opioid in controlled release form as e.g. in form of the “controlled release matrix formulation” or in any other controlled release form as referred to herein. Unless specifically indicated the term “controlled release dosage form” refers to said dosage form in intact form. The dosage form can e.g. be a tablet comprising the compressed controlled release matrix formulation or a capsule comprising the controlled release matrix formulation in the form of multi particulates.
  • Resistance to alcohol extraction can e.g. be tested by subjecting the formulation to Simulated Gastric Fluid (SGF) with 20% ethanol. A typical manner in order to obtain “900 ml of Simulated Gastric Fluid (SGF) with 20% ethanol” is by mixing 800 ml of SGF with 210 ml of 95% ethanol/water (which provides 200 ml ethanol) and taking 900 ml of the mixture. The effect of the additional 10 ml of water from the 95% ethanol will be minimal in the percentages of SGF and ethanol in the 900 ml mixture. Resistance to alcohol extraction can also be tested using an aqueous solution comprising 40% ethanol.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts the in-vitro dissolution results of compositions A-F of Example 5.
  • FIGS. 2 and 3 depict the in-vitro dissolution results of Example 9.
  • FIG. 4 depicts the crushing test results using a Pill Crusher or Spoons of Example 14
  • FIG. 5 depicts the crushing test results using Mortar and Pestle of Example 14
  • FIG. 6 depicts the alcohol extraction test results of Example 14.
  • FIG. 7 depicts the alcohol extraction test results of Examples 15 to 21 described in Example 25.
  • FIG. 8 depicts the dissolution profiles in Simulated Gastric Fluid with 40% alcohol of Examples 15 to 21 described in Example 25
  • FIG. 9 depicts the dissolution profiles in Simulated Gastric Fluid of Examples 15 to 20 described in Example 25
  • FIG. 10 depicts the dissolution profiles in Simulated Gastric Fluid 40% alcohol of Examples 22 to 24 described in Example 25
  • FIG. 11 depicts the dissolution profiles in Simulated Gastric Fluid of Examples 22 to 24 described in Example 25
  • DETAILED DESCRIPTION
  • Drug abusers sometimes try to achieve euphoric effects by manipulating drug formulations to quicken the onset.
  • The most rudimentary way of accomplishing this is by crushing the dosage form into a fine powder in an attempt to make the active ingredient more available. Oral abusers chew and/or swallow the material, and nasal abusers crush the formulations for snorting.
  • For parenteral or intravenous tampering, crushed material is sometimes dissolved in water with heating and filtered into a syringe for injection.
  • In addition to the aforementioned “direct tampering” techniques, more determined abusers can also use various kinds of “kitchen chemistry” in an attempt to completely isolate the active ingredient from a formulation matrix. One method involves one-step extractions into commonly available media such as water or ethanol and mixtures thereof.
  • In certain embodiments, the present invention is directed to a controlled release dosage form comprising a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material; wherein less than 25%, or less than 20% of the opioid salt is released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.°. In certain such embodiments, at least 5%, or 10% opioid analgesic is released under these dissolution conditions. In more detail: In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of matrices comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a pharmaceutically acceptable excipient; and a layer comprising a controlled release material disposed about the matrix. In certain such embodiments, the present invention is directed to a controlled release dosage form comprising a plurality of matrices comprising a pharmaceutically acceptable salt of an opioid analgesic in a pharmaceutically acceptable excipient; and a layer comprising a controlled release material disposed about each of the matrices.
  • In certain such embodiments the controlled release dosage form comprises a controlled release matrix formulation which does not contain more than 15% (by wt), preferably which does not contain more than 20% (by wt) C12 to C36 aliphatic alcohol selected from the group consisting of stearyl alcohol, cetyl alcohol and cetostearyl alcohol.
  • In certain embodiments, the present invention is directed to a controlled release dosage form comprising an opioid analgesic and a controlled release material; wherein the ratio of the amount of opioid analgesic released after 1 hour of in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of opioid analgesic released after 1 hour in-vitro dissolution of the dosage form in 500 ml and/or 900 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is 2:1 or less or less than about 2:1; 1.5:1 or less or less than about 1.5:1; or 1:1 or less or less than about 1:1. In certain such embodiments, the lower limit of this ratio is 0.5:1 or 1:1.
  • In certain such embodiments the controlled release dosage form comprises a controlled release matrix formulation which does not contain more than 15% (by wt), preferably which does not contain more than 20% (by wt) C12 to C36 aliphatic alcohol selected from the group consisting of stearyl alcohol, cetyl alcohol and cetostearyl alcohol.
  • In certain embodiments the present invention is directed to the use of a sparingly water permeable thermoplastic polymer as controlled release matrix material in the manufacture of an opioid controlled release matrix formulation to impart resistance to alcohol extraction, wherein said formulation after 15 minutes shaking in 40% ethanol at room temperature using a Stuart Scientific Flask Shaker Model SF1 set at 500 to 600 oscillations per minute releases less than 35% of opioid. In certain such embodiments said formulation releases less than 30%, more preferred less than 25% of opioid salt, or from 15 to 25% opioid salt.
  • In certain embodiments the present invention is directed to the use of a hydrophobic material polymer as controlled release matrix material in the manufacture of an opioid controlled release matrix formulation to impart resistance to alcohol extraction, wherein less than 25% of the opioid is released after 1 hour of in-vitro dissolution of a dosage form comprising said formulation in 500 ml and/or 900 ml of Simulated Gastric Fluid with 20% ethanol using USP Apparatus I (basket) operating at 100 rpm at 37° C.
  • In certain embodiments the present invention is directed to the use of a hydrophobic material as controlled release matrix material in the manufacture of an opioid controlled release matrix formulation to impart resistance to alcohol extraction, wherein the ratio of the amount of opioid released after 1 hour of in-vitro dissolution of the dosage form comprising said formulation in 900 and/or 500 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37° C., to the amount of opioid released after 1 hour of in-vitro dissolution of the dosage form comprising said formulation in 900 and/or 500 ml of Simulated Gastric Fluid with 0% ethanol using an USP Apparatus I (basket) apparatus at 100 rpm at 37° C., is less than about 2:1.
  • In any of the embodiments disclosed herein, the dosage form can comprise a matrix comprising the opioid analgesic and the controlled release material; a plurality of matrices comprising the opioid analgesic and the controlled release material; a matrix comprising the opioid analgesic and a pharmaceutically acceptable excipient and a layer comprising a controlled release material disposed about the matrix; or a plurality of matrices comprising the opioid analgesic and a pharmaceutically acceptable excipient and a layer comprising a controlled release material disposed about each of the matrices. This list is not meant to be exclusive.
  • In certain embodiments, the dosage form can comprise an opioid analgesic in an osmotic core with a semipermeable membrane surrounding the core. The dosage form can have an optional passageway for osmotic delivery of the opioid analgesic upon administration.
  • In certain embodiments of the present invention, the controlled release material comprises a hydrophobic material, preferably an alkylcellulose, and most preferably ethylcellulose. In certain embodiments of the present invention, the controlled release material comprises a sparingly water permeable thermoplastic polymer, preferably an alkylcellulose, and most preferably ethylcellulose.
  • In certain embodiments of the invention the above said hydrophobic material or said sparingly water permeable thermoplastic polymer is used to impart resistance to alcohol extraction as described herein. The embodiments described below provide a more detailed description of the use of said hydrophobic material or said sparingly water permeable thermoplastic polymers to impart resistance to alcohol extraction.
  • In certain embodiments, the ethylcellulose is present in a weight amount of at least 40%, at least 45%, at least 50%, at least 55% or at least 60% of the matrix or matrices. In other embodiments, the ethylcellulose is present in a weight amount of at most 70%, at most 80% or at most 90% of the matrix or matrices.
  • In certain embodiments the present invention is directed to the use of alkyl cellulose, preferably ethyl cellulose, in an amount from 5 to 60% (by wt) of the controlled release matrix formulation, preferably from 10 to 50% (by wt), most preferably from 20 to 45% (by wt) of the controlled release matrix formulation.
  • In certain embodiments the present invention is directed to the use of ethyl cellulose in combination with at least a second controlled release matrix material selected from a polymethacrylate polymer, preferably a neutral water-insoluble poly (ethyl acrylate, methyl methacrylate) copolymer.
  • In certain embodiments, comprising an alkylcellulose, the controlled release material further comprises a polymethacrylate polymer in a weight amount of at least 5%, at least 10%, at least 15%, at least 20% or at least 25% of the matrix or matrices. In other embodiments, the polymethacrylate polymer is present in a weight amount of at most 30%, or at most 35% of the matrix or matrices.
  • In certain embodiments comprising alkyl cellulose, preferably ethyl cellulose, the controlled release matrix formulation further comprises a polymethacrylate polymer, preferably a neutral water-insoluble poly(ethyl acrylate, methyl acrylate) copolymer in an amount of 5% to 66% (by wt), preferably 15% to 50% (by wt), more preferred 20% to 45% (by wt) and most preferred 25% to 45% (by wt) of the controlled release matrix formulation.
  • In one aspect, the controlled release pharmaceutical formulation may be obtained or is obtainable by melt extrusion and may include a neutral poly(ethyl acrylate, methyl methacrylate) copolymer and an active ingredient. The rubber-like characteristics of this polymer provide multi particulates which typically are elastic and compressible without breaking, and are preferably resilient.
  • In one preferred form, the multi particulates may be compressed by hand between two rigid surfaces, for example a coin and a tabletop or between two spoons, without breaking. The multi particulates may be distorted but may not break or shatter and may ideally reassume more or less their original shape.
  • Rubbery characteristics help impart resistance to tamper. Tamper resistance is of especial importance for products containing opioid analgesics or other active ingredients which are subject to abuse. The tamper resistance of preferred multi particulates of the invention can be demonstrated by shaking a dosage amount of multi particulates in water and/or ethanol, for example 40% ethanol.
  • When tested in this way, preferred multi particulates will show at least one of the following release characteristics of active agent:
  • 15 minutes shaking in water at room temperature: less than 15, less than 10% release of active agent, preferably less than 7.5% release of active agent, more preferably less than 5% release of active agent, for example 1.5 to 4% release of active agent.
    5 minutes standing in water at 50° C. followed by 15 minutes shaking at the same temperature: less than 20% release of the active agent, preferably less than 15% release of active agent, more preferably less than 12% release of active agent, for example 4 to 12% release of active agent.
    5 minutes standing at 75° C. followed by 15 minutes shaking at the same temperature: less than 25% release of active agent, preferably less than 20% release of active agent, more preferably less than 15% release of active agent, for example 10 to 15% release of active agent.
    5 minutes standing at 100° C. followed by 15 minutes shaking at the same temperature: less than 30′% release of active agent, preferably less than 25% release of active agent, more preferably less than 20% release of active agent, for example 12 to 20% release of active agent.
    15 minutes shaking in 40% ethanol at room temperature: less than 35% release of active agent, preferably less than 30% release of active agent, more preferably less than 25% release of active agent, for example 15 to 20% release of active agent.
  • Alternatively, the tamper resistance of preferred multi particulates of the invention can be demonstrated by subjecting a dosage amount of multi particulates to grinding in a mortar and pestle with 24 rotations of the pestle and the product placed in 900 ml water at 37° C. for 45 minutes. The amounts of active agent extracted can then be determined by HPLC and detection UV for instance at 210 nm wavelength.
  • When tested using this method, preferred multi particulates according to the invention will show the following release characteristics of active agent; less than 12.5% release agent, preferably less than 10% release of active agent, more preferably less than 7.5% release of active agent, for example 2 to 7.5% release of active agent.
  • In a further method, the tamper resistance of preferred multi particulates of the invention can be demonstrated by crushing a dosage amount of multi particulates between two spoons or in a pill crusher, such as a Pill Pulverizer as sold by Apex Healthcare Products, and then extracting in 2 ml water heated to boiling on a spoon and filtered off. The amounts of active agent extracted can then be determined by HPLC and detection by UV for instance at 210 mm wavelength.
  • When tested using this method, preferred multi particulates according to the invention will show the following release characteristics of active agent; less than 27.5% release of active agent, preferably less than 15% release of active agent, more preferably less than 5% release of active agent, for example 1 to 5% release of active agent.
  • For imparting such tamper resistance, the present invention may include the use of a neutral poly(ethyl acrylate, methylacrylate) copolymer in the preparation of a pharmaceutical formulation to provide resistance to tamper. A neutral poly(ethyl acrylate, methyl methacrylate) copolymer may be incorporated with the active ingredient in the formulation.
  • In certain embodiments of the present invention, the dosage form further comprises a binder in a weight amount of at least 1%, at least 3%, or at least 5% of the matrix or matrices. In other embodiments, the binder is in a weight amount of at most 7%, or at most 10% of the matrix or matrices. In certain embodiments, the binder is a hydroxyalkylcellulose such as hydroxypropylcellulose or hydroxypropylmethylcellulose.
  • In certain embodiments of the present invention, the dosage form further comprises a plasticizer in a weight amount of at least 3%, at least 5%, at least 15%, or at least 25% of the matrix or matrices. In other embodiments, the plasticizer is in a weight amount of at most 30%, or at most 40% of the matrix or matrices.
  • In certain embodiments, the plasticizer has a melting point of at least 80° C. This helps to minimize the dissolution of the dosage form in hot water in an attempt to liberate the opioid analgesic contained therein. In certain embodiments, the plasticizer is hydrogenated castor oil.
  • A hot water extraction test may be performed as follows: Place one dosage unit of each drug product into two separate glass scintillation vials and label the vials 1 and 2. Add 10 mL of extraction solvent to each vial. If specified, place the vials in a water bath set to a specified temperature (50, 75 or 100° C.) for 5 minutes. Place both vials on a laboratory wrist-action shaker and remove vial 1 after 15 minutes and vial 2 after 120 minutes. Samples at room temperature are placed directly onto the shaker.
  • In certain such embodiments the ratio of the weight % amount of the opioid analgesic released at 50° C., 120 minutes shaking, based on the total amount of opioid in the tested controlled release formulation or dosage form, to the weight % amount of opioid analgesic released at RT 120 minutes shaking, based on the total amount of opioid in the tested controlled release formulation or dosage form is 1.2 or less, preferably 1 or less or 0.9 or less.
  • In certain such embodiments the ratio of the weight % amount of the opioid analgesic released at 75° C., 15 minutes shaking, based on the total amount of opioid in the tested controlled release formulation or dosage form, to the weight % amount of opioid analgesic released at RT 15 minutes shaking, based on the total amount of opioid in the tested controlled release formulation or dosage form is 1.2 or less, preferably 1 or less or 0.9 or less.
  • In certain such embodiments the ratio of the weight % amount of the opioid analgesic released at 100° C., 15 minutes shaking, based on the total amount of opioid in the tested controlled release formulation or dosage form, to the weight % amount of opioid analgesic released at RT 15 minutes shaking, based on the total amount of opioid in the tested controlled release formulation or dosage form is 1.3 or less, preferably 1.2 or less or 0.9 or less.
  • In certain such embodiments the ratio of the weight % amount of the opioid analgesic released at 100° C., 120 minutes shaking, based on the total amount of opioid in the tested controlled release formulation or dosage form, to the weight % amount of opioid analgesic released at RT 120 minutes shaking, based on the total amount of opioid in the tested controlled release formulation or dosage form is less than 2, preferably 1.5 or less or 1 or less or 0.9 or less.
  • In certain embodiments the amount of the alkyl cellulose, preferably ethyl cellulose, is less than 20% (by wt), preferably less than 15% (by wt), most preferred less than 10% (by wt) but more than 5% (by wt) of the controlled release matrix formulation.
  • In more detail: In such certain embodiments preferably the alkyl cellulose, especially ethyl cellulose, is used in the form of particles or aqueous alkyl cellulose dispersions.
  • In case of ethyl cellulose particles, the ethyl cellulose has preferably a viscosity in the range of 3 to 110 cP, when measured in a 5% solution at 25° C. in an Ubbelohde viscosimeter with a solvent of 80% toluene and 20% alcohol. Preferably, the viscosity is in the range of 18 to 110 cP and most preferred in the range of 41-49 cP. A suitable ethyl cellulose is provided by Dow Chemical Company under the trade name Ethocel™ Standard 45. An alternative ethyl cellulose is Ethocel™ Standard 7.
  • In case of aqueous ethyl cellulose dispersions, a dispersion of ethyl cellulose 20 eP with dibutyl/sebacate, ammoniumhydroxide, oleic acid and colloidal anhydrous silica is preferred, which is available under the trade name Surlease™ E-7-7050.
  • In certain embodiments the present invention is directed to the use of ethyl cellulose in combination with at least one plasticizer or second controlled release matrix material selected from C12 to C36 aliphatic alcohols and the corresponding aliphatic acids, preferably stearyl alcohol, cetyl alcohol and cetostearyl alcohol and the corresponding stearic and palmitic acids and mixtures thereof, wherein the amount of C12 to C36 aliphatic alcohol or aliphatic acid is preferably at least 5%, more preferred at least 10% (by wt), more preferred at least 15% (by wt) and most preferred 20% to 25% (by wt) of the controlled release matrix formulation.
  • In such certain embodiments of the invention, the dosage form may comprise, besides the alkyl (ethyl) cellulose and/or the fatty alcohol, fillers and additional substances, such as granulating aids, lubricants, dyes, flowing agents and plasticizers.
  • Lactose, glucose or saccharose, starches and their hydrolysates, microcrystalline cellulose, cellatose, sugar alcohols such as sorbitol or mannitol, polysoluble calcium salts like calciumhydrogenphosphate, dicalcium- or tricalciumphosphat may be used as fillers.
  • Povidone may be used as granulating aid.
  • Highly-dispersed silica (Aerosil®), talcum, corn starch, magnesium oxide and magnesium- or calcium stearate may preferably be used as flowing agents or lubricants.
  • Magnesium stearate and/or calcium stearate can be preferably be used as lubricants. Fats like hydrogenated castor oil can also preferably be used.
  • According to such certain embodiments, a formulation is especially preferred which comprises ethylcellulose, stearyl alcohol, magnesium stearate as lubricant, lactose as filler and providone as a granulating aid.
  • In certain such embodiments the present invention the controlled release matrix formulation does not comprise a neutral water insoluble poly (ethyl acrylate methyl acrylate) copolymer and/or a poly(meth)acrylate trimethylammoniummethylacrylate chloride copolymer.
  • In certain such embodiments of the present invention, the hydrophobic material is an enteric polymer. Examples of suitable enteric polymers include cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, methacrylic acid copolymer, shellac, hydroxypropylmethylcellulose succinate, cellulose acetate trimellitate, and mixtures of any of the foregoing.
  • The dosage form of the present invention can be prepared by extrusion or by granulation in accordance with the teachings of, e.g., U.S. Pat. Nos. 5,266,331; 5,958,452; and 5,965,161.
  • In certain embodiments, in particular embodiments comprising alkyl cellulose, e.g. ethyl cellulose, in combination with fatty alcohols or fatty acids as described above (i.e. the C12 to C36 aliphatic alcohols and the corresponding aliphatic acids), the production of pharmaceutical formulations or preliminary stages thereof, which are in accordance with the invention, by extrusion technology is especially advantageous. In one preferred embodiment, pharmaceutical formulations or preliminary stages thereof are produced by melt extrusion with co- or counter-rotating extruders comprising two screws. Another such preferred embodiment is the production by means of extrusion, with extruders comprising one or more screws. These extruders may also comprise kneading elements.
  • Extrusion is also a well-established production process in pharmaceutical technology and is well known to the person skilled in the art. The person skilled in the art is well aware that during the extrusion process, various parameters, such as the feeding rate, the screw speed, the heating temperature of the different extruder zones (if available), the water content, etc. may be varied in order to produce products of the desired characteristics.
  • The aforementioned parameters will depend on the specific type of extruder used. During extrusion the temperature of the heating zones, in which the components of the inventive formulation melt, may be between 40 to 120° C. or between 40 to 160° C., preferably between 50 to 100° C. or preferably between 50 to 135° C., more preferably between 50 to 90° C., even more preferably between 50 to 70° C. and most preferably between 50 to 65° C., particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used. The person skilled in the art is well aware that not every heating zone has to be heated. Particularly behind the feeder where the components are mixed, cooling at around 25° C. may be necessary. The screw speed may vary between 100 to 500 revolutions per minute (rpm), preferably between 100 to 250 rpm, more preferably between 100 to 200 rpm and most preferably around 150 rpm, particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used. The geometry and the diameter of the nozzle may be selected as required. The diameter of the nozzle of commonly used extruders typically is between 1 to 10 mm, preferably between 2 to 8 mm and most preferably between 3 to 5 mm. The ratio of length versus diameter of the screw of extruders that may be used for production of inventive preparations is typically around 40:1.
  • Generally, the temperatures of the heating zones have to be selected such that no temperatures develop that may destroy the pharmaceutically active compounds. The feeding rate and screw speed will be selected such that the pharmaceutically active compounds are released from the preparations produced by extrusion in a sustained, independent and invariant manner. If e.g. the feeding rate is increased, the screw speed may have to be increased correspondingly to ensure the same retardation.
  • The person skilled in the art knows that all the aforementioned parameters depend on the specific production conditions (extruder type, screw geometry, number of components etc.) and may have to be adapted such that the preparations produced by extrusion provide for the required release.
  • According to such certain embodiments the C12 to C36 aliphatic alcohol or aliphatic acid melts and the ethylcellulose can be dissolved in said C12 to C36 aliphatic alcohol or aliphatic acid during the melt extrusion process.
  • Opioid agonists salts useful in the present invention include, but are not limited to, pharmaceutically acceptable salts of any of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papavereturn, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing, and the like. In certain embodiments, the amount of the opioid agonist in the dosage form may be about 75 ng to 750 mg.
  • Opioid antagonist or pharmaceutically acceptable salts thereof useful in combination with opioid agonists or pharmaceutically acceptable salts thereof as described above are naloxone, naltrexone and nalorphine or pharmaceutically acceptable salts thereof. Preferred is the combination of oxycodone HCl and naloxone HCl in an amount ratio of 2:1.
  • In certain embodiments, the opioid is selected from codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts thereof.
  • In certain other embodiments other therapeutically active agents/actives may be used in accordance with the present invention, either in combination of opiods or instead of opioids. Examples of such therapeutically active agents include antihistamines (e.g., dimenhydrinate, diphenhydramine, chlorpheniramine and dexchlorpheniramine maleate), non-steroidal anti-inflammatory agents (e.g., naproxen, diclofenc, indomethacin, ibuprofen, sulindac), anti-emetics (e.g., metoclopramide, methylnaltrexone), anti-epileptics (e.g., phenyloin, meprobmate and nitrazepam), vasodilators (e.g., nifedipine, papaverine, diltiazem and nicardipine), anti-tussive agents and expectorants (e.g. codeine phosphate), anti-asthmatics (e.g. theophylline), antacids, anti-spasmodics (e.g. atropine, scopolamine), antidiabetics (e.g., insulin), diuretics (e.g., ethacrynic acid, bendrofluthiazide), anti-hypotensives (e.g., propranolol, clonidine), antihypertensives (e.g., clonidine, methyldopa), bronchodilatiors (e.g., albuterol), steroids (e.g., hydrocortisone, triamcinolone, prednisone), antibiotics (e.g., tetracycline), antihemorrhoidals, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, vitamins, stimulants (including appetite suppressants such as phenylpropanolamine), as well as pharmaceutically acceptable salts, hydrates, and solvates of the same.
  • The present invention is also directed to the dosage forms utilizing active agents such as for example, benzodiazepines, barbiturates or amphetamines. These may be combined with the respective antagonists
  • The term “benzodiazepines” refers to benzodiazepines and drugs that are derivatives of benzodiazepine that are able to depress the central nervous system. Benzodiazepines include, but are not limited to, alprazolam, bromazepam, chlordiazepoxied, clorazepate, diazepam, estazolam, flurazepam, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, methylphenidate as well as pharmaceutically acceptable salts, hydrates, and solvates and mixtures thereof. Benzodiazepine antagonists that can be used in the present invention include, but are not limited to, flumazenil as well as pharmaceutically acceptable salts, hydrates, and solvates.
  • Barbiturates refer to sedative-hypnotic drugs derived from barbituric acid (2, 4, 6,-trioxohexahydropyrimidine). Barbiturates include, but are not limited to, amobarbital, aprobarbotal, butabarbital, butalbital, methohexital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital and as well as pharmaceutically acceptable salts, hydrates, and solvates mixtures thereof. Barbiturate antagonists that can be used in the present invention include, but are not limited to, amphetamines as well as pharmaceutically acceptable salts, hydrates, and solvates.
  • Stimulants refer to drugs that stimulate the central nervous system. Stimulants include, but are not limited to, amphetamines, such as amphetamine, dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate as well as pharmaceutically acceptable salts, hydrates, and solvates and mixtures thereof. Stimulant antagonists that can be used in the present invention include, but are not limited to, benzodiazepines, as well as pharmaceutically acceptable salts, hydrates, and solvates as described herein.
  • In certain embodiments, the opioid is hydromorphone hydrochloride in an amount, e.g., of 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg or 64 mg hydromorphone hydrochloride.
  • In certain embodiments, the opioid is oxycodone hydrochloride in an amount, e.g., of 5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg oxycodone hydrochloride. In certain embodiments, in particular embodiments comprising alkyl cellulose e.g. ethylcellulose in combination with fatty alcohol oxycodone hydrochloride is combined in the above amounts with naloxone hydrochloride in an amount ratio of 2:1.
  • The present invention will now be more fully described with reference to the accompanying examples. It should be understood, however, that the following description is illustrative only and should not be taken in any way as a restriction of the invention.
  • EXAMPLES OF THE INVENTION Example 1 Comparative Example
  • Example 1 is the approved Palladone (sustained release hydromorphone hydrochloride) formulation and contains the following ingredients:
  • Hydromorphone HCl 12.0 mg
    Eudragit RSPO* 76.5 mg
    Ethylcellulose  4.5 mg
    Stearyl alcohol 27.0 mg
    *(poly(meth)acrylate with 5% trimethylammoniummethacrylate chloride)
  • The formulation was prepared by the following procedure:
      • 1. Mill the stearyl alcohol.
      • 2. Blend the Hydromorphone HCl, ethylcellulose, Eudragit RSPO and milled stearyl alcohol on a v-blender
      • 3. Extrude the blend from (1) using a ZSE-218 extruder fitted with counter-rotating screws, and a 1 mm die plate. Using a pelletizer, cut the strands to create cylindrical pellets approximately 1 mm long and 1 mm in diameter.
    Example 2.1 Example 2.1
  • The composition of Example 2.1 is summarized below.
  • Amt/unit Amt/batch
    Ingredient (Trade Name) (mg) (g)
    Hydromorphone HCl 12.0 221.1*
    Ethycellulose (Ethocel Std. Premium 7) 61.0 1,118.3
    Glyceryl palmitostearate (Precirol ATO 5) 27.0 495.0
    Hydroxypropyl Cellulose (Klucel EF) 20.0 366.7
    Total 120.0 2201.1
    *Weigh corrected for water and impurities (99.5% based on Certificate of Analysis)
  • The processing conditions at the time of sampling are summarized below.
  • Extruder: Leistritz ZSE 27 Screw Configuration: Counter-rotation
  • Heating Zone 1 2 3-6 7-8 9-10 11-12
    Temperature (° C.) 15 40 125 125 125 124-125
  • Condition #1 Torque (%): 25
  • Melt Pressure (psi): 480
    Feed rate (kg/hour): 2.9
    Screw speed (rpm): 90
    Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
  • Condition #2 Torque (%): 25
  • Melt Pressure (psi): 520
  • Feed rate (kg/hour): 4.2
  • Screw speed (rpm): 90
    Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
  • The processing steps for manufacturing the Hydromorphone HCl 12 mg melt extruded multi particulates are as follows:
      • 1. Screening: The Ethylcellulose, Hydromorphone HCl, Hydroxypropyl Cellulose and Glyceryl Palmitostearate were screened through a #20 US mesh screen (in that order).
      • 2. Blending: The materials screened in Step 1 were loaded into an 8 qt. V-blender with intensifier bar and blended for 10 minutes at ambient temperature.
      • 3. Extrusion: Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed into approximately 1 mm strands. The extruder was set on counter-rotation with zone (barrel) temperatures ranged from 15° C. to 125° C.
      • 4. Cooling: The strands were cooled on a conveyor at ambient temperature.
      • 5. Pelletizing: The cooled strands were cut into pellets approximately 1 mm in length using a pelletizer.
      • 6. Screening: The pellets were screened through a #16 US mesh screen and a #20 US mesh screen. The pellets retained on the #20 US mesh screen were collected.
    Example 2.2
  • Example 2.2 compares the impact of various concentrations of ethanol in simulated gastric fluid (500 ml in Example 1; 900 ml in Example 2.1) using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° on the dissolution of the current Palladone formulation and the formulation of Example 2.1 containing the same concentration of hydromorphone (19% w/w). The current Palladone formulation contains an ammonio methacrylate copolymer as the primary release-rate controlling excipient whereas the formulation of Example 2.1 contains ethylcellulose. The results are summarized below.
  • Bath Vessel 60 minutes
    Example 1 1 (SGF Media) 11%
    2 (10% EtOH in SGF) 39%
    3 (15% EtOH in SGF) 64%
    4 (20% EtOH in SGF) 88%
    5 (40% EtOH in SGF) 97%
    Example 2.1 1 (SGF Media, pH = 1.27) 13%
    2 (11% EtOH in SGF) 15%
    3 (20% EtOH in SGF) 19%
    4 (25% EtOH in SGF) 23%
    5 (35% EtOH in SGF) 33%
    6 (SIF Media, pH = 7.43) 13%
  • The data show that the formulation of Example 2.1 is more resistant to increases in the drug release in the presence of ethanol. For example, for the current Palladone formulation, concentrations of 20% ethanol in SGF resulted in 8× the amount of hydromorphone to be released in one hour compared to the amount released in SGF. The same concentration of ethanol results in an increase of approximately 1.5× the amount of hydromorphone release for the formulation of Example 2.1 containing ethylcellulose as the rate limiting polymer.
  • Example 3 Example 3.1
  • The composition of Example 3.1 is summarized below.
  • Amt/unit
    Ingredient (Trade Name) (mg) Batch (gm)
    Hydromorphone HCl 12.0 168.84*
    Ethycellulose (Ethocel Std. Premium 7) 61.0 854.0
    Hydrogenated Castor Oil 27.0 378.0
    Hydroxypropyl Cellulose (Klucel EF) 20.0 280.0
    Total 120.0 1680.84
    *weight corrected for water and impurities—99.5% based on Certificate of Analysis
  • The processing conditions at the time of sampling are summarized below.
  • Extruder: Leistritz ZSE 27 Screw Configuration: Counter-rotation
  • Heating Zone 1 2 3-6 7-8 9-10 11-12
    Temperature (° C.) 15 45 100-125 100-125 100-125 100-125

    Condition #1 (Barrel temp 100 C)
  • Torque (%): 46
  • Melt Pressure (psi): 2000
    Feed rate (kg/hour): 2.9
    Screw speed (rpm): 90
    Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
    Condition #2 (Barrel temp 125 C)
  • Torque (%): 25
  • Melt Pressure (psi): 690
    Feed rate (kg/hour): 2.9
    Screw speed (rpm): 90
    Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
  • The processing steps for manufacturing the Hydromorphone HCl 12 mg melt extruded multi particulates are as follows:
      • 7. Screening: The Ethylcellulose, Hydromorphone HCl, Hydroxypropyl Cellulose and Hydrogenated Castor Oil were screened through a #20 US mesh screen (in that order).
      • 8. Blending: The materials screened in Step 1 were loaded into an 8 qt. V-blender with intensifier bar and blended for 10 minutes at ambient temperature.
      • 9. Extrusion: Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed into approximately 1 mm strands. The extruder was set on counter-rotation with zone (barrel) temperatures ranged from 15° C. to 125° C.
      • 10. Cooling: The strands were cooled on a conveyor at ambient temperature.
      • 11. Pelletizing: The cooled strands were cut into pellets approximately 1 mm in length using a pelletizer.
      • 12. Screening: The pellets were screened through a #16 US mesh screen and a #20 US mesh screen. The pellets retained on the #20 US mesh screen were collected.
        • Testing—Extraction in water at RT and Elevated Temperature Procedure
    Example 3.2
  • Example 3.2 compares the resistance to hot water extraction. Place one dosage unit of each drug product into two separate glass scintillation vials and label the vials 1 and 2. Add 10 mL of extraction solvent to each vial. If specified, place the vials in a water bath set to a specified temperature (50, 75 or 100° C.) for 5 minutes. Place both vials on a laboratory wrist-action shaker and remove vial 1 after 15 minutes and vial 2 after 2 hours. Samples at room temperature are placed directly onto the shaker. The experimental set-up is listed below.
  • Exper- Extraction Extraction Heating
    iment: Solvent Temperature Time Shaking Times
    A Water Room N/A 15 minutes & 2 hours
    Temperature
    B Water 50° C. 5 minutes 15 minutes & 2 hours
    C Water 75° C. 5 minutes 15 minutes & 2 hours
    D Water 100° C.  5 minutes 15 minutes & 2 hours
  • The results of the extraction tests are presented below.
  • % hydromorphone HCl released (multiple
    of RT in parentheses)
    Temperature Time Example 2.1 Example 3.1
    RT  15 mins 6.6 11.2
    120 mins 6.3 12.9
    50 C.  15 mins 4.9 (<1) 9.0 (<1)
    120 mins 7.9 (1.3) 9.6 (<1)
    75 C.  15 mins 8.9 (1.3) 9.5 (<1)
    120 mins 6.2 (<1) 11.0 (<1)
    100 C.   15 mins 9.1 (1.4) 12.4 (1.1)
    120 mins 12.9 (2.0) 11.8 (<1)
  • Example 4
  • Example 4 is directed to formulations comprising ethylcellulose and poylmethacrylate.
  • Example 4.1 Prophetic
  • In Example 4.1, the following formulation can be prepared. The formulation may consist of a combination of the following ingredients: drug, ethylcellulose, polymethacrylate, and hydroxypropyl cellulose. An example formulation is presented below.
  • g per % per
    Ingredient batch batch Ingredient Function Examples
    Drug 120 g 13.6% Active Opioids
    Pharmaceutical
    Ingredient
    Ethylcellulose 520 g 59.1% Hydrophobic film Ethocel
    forming agent,
    control release agent
    Polymethacrylate 200 g 1 22.7% Permeable, flexible Eudragit
    (aqueous (500 g) film forming agent, NE40D
    dispersion) control release agent
    Hydroxypropyl  40 g 4.6% Granulating binder Klucel
    Cellulose
    1 200 g of solids from an aqueous dispersion containing 40% solids. The range of materials that could be used within this formulation may include other control release agents such as methacrylic acid copolymers (Eudragits), and other cellulose based binding agents such as methylcellulose (Methocel) or hydroxyethyl cellulose (Natrosol)..
  • The manufacturing process utilizes standard/conventional pharmaceutical processes: wet granulation, drying, milling, and compression. The granulation process produces a typical granulation (i.e., it resembles a free flowing granular powder); however, when the granulation is compressed, the granules fuse together creating a hard tablet which is resistant to tampering. The manufacturing process is described below.
      • a. Dry mix the ethylcellulose, API (or spray dried lactose for placebo evaluation) and hydroxypropyl cellulose in a low/high shear mixer.
      • b. While mixing, add the polymethacrylate (aqueous dispersion) and continue mixing in the low/high shear mixer until a granulation forms.
      • c. Dry the wet granulation in a fluid bed dryer (or screen on oven trays and dry).
      • d. Based on the required need, the dried granulation can be:
        • compressed directly using a tablet press.
        • sieved to provide specific particle size fractions for compression or for further blending (e.g., lubricant, additional binder).
        • milled to reduce the particle size (creating a more uniform particle size profile) that could be directly compressed, blended with other ingredients (e.g., lubricant, additional binder), or screened to provide specific particle size fractions for compression or for further blending.
        • Milling can be achieved using a screening mill (such as a rotating impeller or oscillating bar).
      • e. Compress tablets to target weight on a rotary tablet press.
  • Further examples 4.2 to 4.8 including ethylcellulose and polymethacrylate.are presented below.
  • Example 4.2
  • The composition for EXAMPLE 4.2 is below.
  • g per % per
    Ingredient batch batch
    Hydromorphone HCl 150 g 10%
    Microcrystalline 150 g 10%
    Cellulose, Avicel PH
    101
    Ethylcellulose, Ethocel 600 g 40%
    Standard 7
    Polymethacrylate 450 g 1 30%
    (aqueous dispersion) (1125 g) 
    Eudragit NE40D
    Hydroxypropyl 150 g 10%
    Cellulose Klucel EF
    1 450 g of solids from an aqueous dispersion containing 40% solids.
  • The processing steps for manufacturing the Hydromorphone HCl tablets are as follows:
      • f. Dry mix the Ethylcellulose, Hydromorphone HCl, Microcrystalline Cellulose and Hydroxypropyl Cellulose in a low/high shear mixer.
      • g. While mixing, add the Polymethacrylate (aqueous dispersion) and continue mixing in the low/high shear mixer until a granulation fo ms.
      • h. Dry the wet granulation in a fluid bed dryer (or screen onto oven trays and dry).
      • i. Mill the dried granulation using a screening mill (such as a rotating impeller or oscillating bar).
      • j. Compress the milled granulation to target weight on a rotary tablet press.
  • Tablets were compressed to a weight of 120 mg to target a 12 mg dose. The resultant tablet composition is provided below.
  • mg/unit
    Hydromorphone HCl 12
    MCC (Avicel 101) 12
    Ethocel Standard 7 48
    Eudragit NE40D 36
    HPC (Klucel EF) 12
    120 mg
  • The tablets were tested in vitro using USP Apparatus 2 (paddle) in simulated gastric fluid, simulated intestinal fluid, in 11% Ethanol and 35% Ethanol. The results are presented below.
  • 11% 35%
    SGF SIF EtOH EtOH
    1 hr 43 40 42 35
    2 hr 60 56 59 47
  • Examples 4.3 to 4.5
  • Compositions of Examples 4.3, 4.4 and 4.5 are summarized below.
  • EXAMPLE
    4.3 4.4 4.5
    g per % per g per % per g per % per
    Ingredient batch batch batch batch batch batch
    Hydromorphone HCl 100 g 11.8% 100 g 11.8% 100 g 11.8%
    Ethylcellulose 600 g 70.6% 500 g 58.8% 400 g 47.1%
    Polymethacrylate 100 g 1 11.8% 200 g 1 23.5% 300 g 1 35.3%
    (aqueous dispersion) (250 g) (500 g) (750 g)
    Hydroxypropyl  50 g  5.9%  50 g  5.9%  50 g  5.9%
    Cellulose
    1 Amount of solids from an aqueous dispersion containing 40% solids.
  • The processing steps for manufacturing the Hydromorphone HCl tablets are as follows:
      • a. Dry mix the Ethylcellulose, Hydromorphone HCl, and Hydroxypropyl Cellulose in a low/high shear mixer.
      • b. While mixing, add the Polymethacrylate (aqueous dispersion) and continue mixing in the low/high shear mixer until a granulation forms.
      • c. Dry the wet granulation in a fluid bed dryer (or screen onto oven trays and dry).
      • d. Mill the dried granulation using a screening mill (such as a rotating impeller or oscillating bar).
      • e. Compress the milled granulation to target weight on a single station tablet press.
      • f. Cure the tablets in an oven.
  • Tablets were compressed to a weight of 102 mg to target a 12 mg dose as presented below.
  • EXAMPLE
    4.3 4.4 4.5
    Granulation Tablet Granulation Tablet Granulation Tablet
    Ingredient mg/unit mg/unit mg/unit mg/unit mg/unit mg/unit
    Hydromorphone HCl 10 12 10 12 10 12
    Ethylcellulose 60 72 50 60 40 48
    Polymethacrylate 10 12 20 24 30 36
    (aqueous dispersion)
    Hydroxypropyl 5 6 5 6 5 6
    Cellulose
    Total 85 102 85 102 85 102
  • The tablets were tested in vitro using a USP Apparatus 2 (paddle) at 50 rpm at 37 degrees C. in 900 ml of simulated gastric fluid to evaluate drug release. Drug release data was collected using a UV spectrometer flow through system at a wavelength of 280 nm. The results are presented below.
  • Time
    (hours) 4.3 4.4 4.5
    0.5 15% 17% 16%
    1 20% 24% 23%
    1.5 24% 29% 28%
    2 28% 34% 33%
    2.5 31% 39% 37%
  • Compositions of Examples 4.6, 4.7 and 4.8 are summarized below.
  • EXAMPLE
    4.6 4.7 4.8
    g per % per g per % per g per % per
    Ingredient batch batch batch batch batch batch
    Oxycodone HCl 100 g 10% 100 g 10% 100 g 10%
    Ethylcellulose 550 g 55% 350 g 35% 150 g 15%
    Polymethacrylate 250 g 1 25% 250 g 1 25% 250 g 1 25%
    (aqueous dispersion) (625 g) (625 g) (625 g)
    Hydroxypropyl 100 g 10% 300 g 30% 500 g 50%
    Cellulose
    1 Amount of solids from an aqueous dispersion containing 40% solids.
  • The processing steps for manufacturing the Oxycodone HCl tablets are as follows:
      • a. Dry mix the Ethylcellulose, Oxycodone HCl, and Hydroxypropyl Cellulose in a low/high shear mixer.
      • b. While mixing, add the Polymethacrylate (aqueous dispersion) and continue mixing in the low/high shear mixer until a granulation forms.
      • c. Dry the wet granulation in a fluid bed dryer (or screen onto oven trays and dry).
      • d. Mill the dried granulation using a screening mill (such as a rotating impeller or oscillating bar).
      • e. Compress the milled granulation to target weight on a single station tablet press.
  • Tablets were compressed to a weight of 100 mg to target a 10 mg dose as presented below.
  • Example
    4.6 4.7 4.8
    Tablet Tablet Tablet
    Ingredient mg/unit mg/unit mg/unit
    Hydromorphone HCl 10 10 10
    Ethylcellulose 55 35 15
    Polymethacrylate 25 25 25
    (aqueous dispersion)
    Hydroxypropyl 10 30 50
    Cellulose
    Total 100 100 100
  • The tablets were tested in vitro using a USP Apparatus 2 (paddle) at 50 rpm at 37 degrees C. in 900 ml of simulated gastric fluid to evaluate drug release. Drug release data was collected using a UV spectrometer flow through system at a wavelength of 230 nm. In addition, Example 4.8 was tested in 40% Ethanol/SGF to evaluate the impact of ethanol on drug release. The results are presented below.
  • Time 4.8 in 40%
    (hours) 4.6 4.7 4.8 Ethanol/SGF
    1 43% 55% 36% 45%
    2 71% 77% 50% 66%
    4 94% 92% 67% n/a
    6 95% 97% 79% n/a
    8 95% 98% 87% n/a
    12 95% 99% 96% n/a
  • Example 5
  • Compositions A through F of Example 5 are summarized below.
  • A B C D E F
    Ingredient (Trade Name) (mg) (mg) (mg) (mg) (mg) (mg)
    Hydromorphone HCI 12.0 12.0 12.0 12.0 12.0 12.0
    Ethycellulose (Ethocel Std. 70.0 68.0 66.0 64.0 62.0 60.0
    Premium 7)
    Hydrogenated Castor Oil 15.0 15.0 15.0 15.0 15.0 15.0
    Hydroxypropyl Cellulose 23.0 25.0 27.0 29.0 31.0 33.0
    (Klucel EF)
    Total 120.0 120.0 120.0 120.0 120.0 120.0
  • The processing conditions at the time of sampling are summarized below:
  • Extruder: Leistritz ZSE 27 Screw Configuration Counter-rotation
  • Heating Zone 1 2 3-6 7-8 9-10 11-12
    Temperature (° C.) 15 40 125 125 125 135
  • Conditions.
  • Feed rate (kg/hour): 4.2
    Screw speed (rpm): 90
    Die Plate Hole diameter (mm): 1.0 (8-hole die plate)
  • The processing steps for manufacturing the Hydromorphorphone HCl 12 mg melt extruded multi particulates are as follows:
      • 1. Screening: The Ethylcellulose, Hydromorphone HCl and Hydroxypropylcellulose were screened though a #20 US mesh screen.
      • 2. Blending: The materials screened in Step 1 were loaded into an 8 qt. V-blender with intensifier bar and blended for 10 minutes at ambient temeperature.
      • 3. Extrusion: Materials blended in Step 2 were metered into a twin screw extruder fitted with a die and processed in to approximately 1 mm strands. The extruder was set on counter-rotation with zone (barrel) set-temperatures ranged from 15° C. to 135° C.
      • 4. Cooling: The strands were cooled on a conveyor at ambient temperature.
      • 5. Pelletizing: The cooled strands were cut into pellets approximately 1 mm in length using a pelletizer.
      • 6. Screening: The pellets were screened through a #16 US mesh screen and a #20 US mesh screen. The pellets retained on the #20 US mesh screen were collected.
  • Formulations A, C and F were tested in vitro using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees ° C. in various concentrations of ethanol in 500 ml simulated gastric fluid in order to determine the impact of ethanol on drug release. The results are presented below.
  • % Hydromorphone Released in 60 minutes (ratio to
    Ethanol amount released in SGF)
    concentration (%) A C F Example 1
    0 15 14 20 11
    5 14 16 20 18* (1.6) 
    10 14 15 22 39 (3.5)
    20 14 (0.9) 17 (1.2) 20 (1)   88 (8.0)
    30 27 (1.8) 30 (2.1) 34 (1.7)
    40 39 (2.6) 45 (3.2) 55 (2.8) 97 (8.8)
  • The results above show that hydromorphone release from formulations A, C, and F was unchanged in ethanol concentrations up to and including 20% v/v. This is an improvement on Example 1 (the current Palladone formulation) which has an eight-fold increase in hydromorphone release under these conditions. At 30% and 40% v/v ethanol there was an increase in release for formulations A, C and F but the increases relative to release in SGF were lower than those obtained with Example 1 (the current Palladone formulation).
  • Example 6
  • Oxycodone/naloxone dosage form comprising 10 mg oxycodone hydrochloride and 5 mg naloxone hydrochloride
  • Component weight [mg/tablet]
    Oxycodone hydrochloride1) 10.50
    corresponding to
    Oxycodone hydrochloride anhydrous 10.00
    naloxone hydrochloride dihydrate 5.45
    corresponding to
    Naloxone hydrochloride anhydrous 5.00
    Povidone K30 5.00
    Ethyl cellulose 45 cp 10.00
    Stearyl alcohol 25.00
    Lactose monohydrate 64.25
    Talc 2.50
    Magnesium-Stearate 1.25
    film coating opadry II HP white— 3.72
    85F18422°
    1)calculated based on expected moisture content
    °qualitative composition: see below
  • Example 7
  • Oxycodone/naloxone dosage form comprising 20 mg oxycodone hydrochloride and 10 mg naloxone hydrochloride
  • Component weight [mg/tablet]
    Oxycodone hydrochloride1) 21.00
    corresponding to
    Oxycodone hydrochloride anhydrous 20.00
    naloxone hydrochloride 10.90
    corresponding to
    Naloxone hydrochloride anhydrous 10.00
    Povidone K30 7.25
    Ethyl cellulose 45 cp 12.00
    Stearyl alcohol 29.50
    Lactose monohydrate 54.50
    Talc 2.50
    Magnesium-Stearate 1.25
    film coating opadry II HP pink 85F24151° 4.17
    2)calculated based on expected moisture content
    °qualitative composition: see below
  • Example 8
  • Oxycodone/naloxone dosage form comprising 40 mg oxycodone hydrochloride and 20 mg naloxone hydrochloride
  • Component weight [mg/tablet]
    Oxycodone hydrochloride1) 42.00
    corresponding to
    Oxycodone hydrochloride anhydrous 40.00
    naloxone hydrochloride dihydrate 21.80
    corresponding to
    Naloxone hydrochloride anhydrous 20.00
    Povidone K30 14.50
    Ethyl cellulose 45 cp 24.00
    Stearyl alcohol 59.00
    Lactose monohydrate 109.00
    Talc 5.00
    Magnesium-Stearate 2.5
    film coating opadry II HP yellow 8.33
    85F32109°
    3)calculated based on expected moisture content
    °qualitative composition: see below
  • Qualitative Composition of the Film Coat
  • white pink yellow Reference to
    Opadry II HP 85F18422 85F24151 85F32109 Standard
    Polyvinylalcohol part. + + + Ph. Eur. *
    hydrolized
    Titanium dioxide + + + Ph. Eur. *
    (E 171)
    Macrogol 3350 + + + Ph. Eur. *
    Talcum + + + Ph. Eur. *
    Iron oxide red (E 172) + NF */EC
    Directive
    Iron oxide yellow + NF */EC
    (E 172) Directive
    * current Edition
  • The above described dosage forms were prepared by melt extrusion.
  • Oxycodone hydrochloride and naloxone hydrochloride are blended with povidone, ethylcellulose, stearyl alcohol and lactose, the blend is screened to remove agglomerates and further blended. The blend is melt extruded utilizing a heated twin screw extruder, to form strands which are milled to produce granules. The granules are blended with talc and magnesium stearate, compressed into capsule shaped tablets, which are then film coated.
  • Example 9 Dissolution Test
  • The dissolution apparatus was assembled in accordance with the USP basket/100 rpm/900 ml dissolution media method as described e.g. in USP 23. The specified dissolution media were transferred into each vessel with the bath temperature set to 37.0±0.5° C. All ethanolic media were prepared by transferring the appropriate amount of ethanol in USP Simulated Gastric Fluid (SGF) without pepsin (i.e. 9 mL of ethanol with 891 mL of SGF for a 1% ethanol media).
  • A single tablet was transferred into each vessel. A sample was drawn from each vessel at four time points: 10, 30, 60 and 120 minutes. Using the HPLC test method samples and (corresponding) standards were injected onto the column to determine the amount of oxycodone HCl and naloxone HCl dissolved.
  • Twelve different concentrations of ethanol were tested, 0%, 2%, 4%, 8%, 12%, 16%, 20%, 24%, 28%, 32%, 36% and 40%.
  • Example 9/dissolution results of Example 6
  • dissolution (%) oxycodone
    dissolution (%) naloxone HCl (ratio to HCl (ratio to amount released
    amount released in SGF 0% alcohol) in SGF 0% alcohol)
    % 10 30 60 120 10 30 60 120
    ethanol min. min. min. min. min. min. min. min.
    0 17 29 40 53 16 28 39 53
    2 17 29 39 53 15 28 38 52
    4 18 29 39 52 15 27 37 51
    8 16 27 37 50 14 26 36 49
    12 16 27 36 52 13 25 34 47
    16 14 27 38 50 12 24 33 45
    20 15 25 34(0.9) 45 12 23 32(0.8) 44
    24 13 25 34 45 10 23 32 44
    28 14 25 34 45 11 22 32 44
    32 13 24 33 44 10 22 32 44
    36 13 24 33 45 11 22 31 44
    40 13 24 33(0.8) 45 10 22 31(0.8) 44
  • Example 9/dissolution results of Example 7
  • dissolution (%) oxycodone
    dissolution (%) naloxone HCl(ratio to HCl(ratio to amount released
    amount released in SGF) in SGF)
    % 10 30 60 120 10 30 60 120
    ethanol min. min. min. min. min. min. min. min.
    0 16 28 39 52 16 28 39 53
    2 16 28 39 52 15 28 38 52
    4 16 28 38 52 15 28 38 52
    8 14 26 36 51 14 25 36 49
    12 16 26 37 49 13 25 34 47
    16 15 26 36 49 13 24 34 47
    20 15 24 33(0.8) 45 13 23 32(0.8) 43
    24 14 23 33 45 12 22 32 44
    28 14 24 33 45 13 23 32 44
    32 13 24 32 44 12 22 31 43
    36 14 24 33 44 12 22 32 44
    40 14 24 34(0.9) 46 12 23 33(0.9) 45
  • Example 9/dissolution results of Example 8
  • dissolution (%) oxycodone
    dissolution (%) naloxone HCl(ratio to HCl (ratio to amount released
    amount released in SGF) in SGF)
    % 10 30 60 120 10 30 60 120
    ethanol min. min. min. min. min. min. min. min.
    0 13 23 34 45 13 24 33 46
    2 13 23 33 46 13 23 33 46
    4 13 23 32 44 12 23 32 44
    8 13 23 32 43 12 22 31 43
    12 12 22 30 42 11 21 29 40
    16 11 21 30 41 10 20 28 40
    20 11 20 28(0.8) 39 11 19 27(0.8) 38
    24 11 20 28 38 11 19 27 38
    28 12 20 27 38 11 19 27 38
    32 11 20 28 38 10 19 27 37
    36 11 19 28 38 11 19 27 38
    40 11 19 27(0.8) 38 10 19 27(0.8) 37
  • The dissolution results of Example 6 to 8 are shown in FIGS. 2 and 3. FIG. 2 shows the dissolution (%) of oxycodone after two hours for example 6 (OX/N 10/5 PR), example 7 (OX/N 20/10 PR) and example 9 (OX/N 20/40 PR). FIG. 3 shows the corresponding dissolution (%) of naloxone after two hours.
  • Between 0 and 20% ethanol, the amount of released active even decreases, while between 20 and 40% ethanol the release is stable. This can be observed for oxycodone hydrochloride and naloxone hydrochloride with respect to all three dosage forms of examples 6 to 8.
  • Examples 10 to 13
  • The compositions of Examples 10 to 13 are below.
  • Examples (% w/w)
    Example Example Example Example
    Material 10 11 12 13
    Oxycodone HCl 10.0 10.0 10.0 10.0
    Ethyl cellulose N10 41.8 nil 32.0 nil
    Eudragit RS PO* nil 41.8 nil 22.0
    Eudragit RL PO* nil nil 10.0 20.0
    Stearyl alcohol 14.0 14.0 14.0 14.0
    Eudragit NE 40 D* 34.2 (S), 34.2 (S), 34.0 (S), 34.0 (S),
    [85.5 (D)] [85.5 (D)] [85.0 (D)] [85.0 (D)]
    Total 100   100   100   100  
    S = solid weight
    D = dispersion weight
    *Eudragit RS PO: poly(meth) acrylate with 5% trimethylammoniummethacrylate chloride
    *Eudragit RL PO: poly(meth) acrylate with 10% trimethylammoniummethacrylate chloride
    *Eudragit NE 40 40% dispersion (% w/w), water lost by evaporation
    neutral poly(ethylacrylate methyl methacrylate) copolymer
  • A procedure for preparing multi particulates of Examples 10 to 13 in the form of pellets is approximately:
  • Step 1. The oxycodone was blended for 5 minutes with ethyl cellulose and/or Eudragit RS PO/RL PO and stearyl alcohol in the Gral 10 high shear mixer
  • Step 2. Eudragit NE 40 D dispersion was slowly added by aid of a peristaltic pump onto the blended materials from Step 1 in the Gral 10 mixing bowl, pre-warmed for Examples 12 and 13 to 29° C., whilst maintaining mixing/chopping.
  • Step 3. The application of Eudragit NE 40 D was continued until granule formation occurred—all the Eudragit NE 40 D was added.
  • Step 4. The application of Eudragit NE 40 D was periodically halted to permit scraping of the sides of the mixing bowl.
  • Step 5. After all the Eudragit NE 40 D had been added, the wet granules were extruded through a conventional extruder and then dried in a fluid bed dryer at approximately 44° C.
  • Step 6. The dried granules were cooled to room temperature and collected.
  • Step 7. The granules were then fed at a controlled rate to a Leistritz Micro 18 extruder equipped with a 1.0 mm die-plate, a conveyor and pelletiser and heated stations (zones) torque and melt pressure as follows;
  • Temperature (° C.)
    Example Zones 3-8 Zones 9-10 Melt Pressure (bar) Torque (%)
    10 115-120 115-120 63-72 59-62
    11 110-115 110-115 70-72 50-60
    12  80-105  90-100 73-86 64-72
    13  90-100 100-110 76-96 67-85
  • The feed rate was 2.0 to 2.6 kg/hr and the screw speed 100 to 141 rpm. The extruded strands were carried away from the die-head on a conveyer and cut into cylindrical multi particulates.
  • Hypothetically, an alternate cutting procedure can be considered. Extrudate emerges from the orifices of the die-head of a Leistritz extruder. A rotary cutter with two blades would be used to cut the extruded mix as it emerges under pressure and still molten from the orifices of the die plate. The blades would sweep over the surface of the die-head to pass the orifices. As they expand and cool, the cut extrudate particles would tend to form rounded surfaces.
  • Hypothetically, although in the above Examples a Leistritz Micro 18 extruder could be used, a larger extruder, for example a Leistritz Micro 27, may be preferred to handle materials requiring a higher torque for processing.
  • Example 14
  • The multi particulates from Examples 10 to 13 were tested to determine their potential for tamper resistance as follows:
  • 1) 400 mg of the multi particulates from Examples 10 to 13 were either crushed between two spoons or in a pill crusher, such as a Pill Pulverizer as sold by Apex Healthcare Products, and then extracted in 2 ml water heated to boiling on a spoon and filtered off. The amounts of oxycodone extracted were then determined by HPLC and detection by UV at 210 nm wavelength and are shown in the chart of FIG. 4 and below.
  • Mean Oxycodone Released (mg)*
    Example 10 Example 11 Example 12 Example 13
    Intact 1.54 2.91 17.97 12.04
    Pill Crusher 1.54 2.31 18.90 13.91
    Spoons 1.25 2.75 24.42 15.07
    *Values are the mean of two repetitions of the test.

    2) 400 mg of the multi particulates from Examples 10 to 13 were subjected to grinding in a mortar and pestle with 24 rotations of the pestle and the product placed in 900 ml water at 37° C. for 45 minutes. The amount of oxycodone dissolved was then determined by the method described in 1) above and the results are represented in the bar chart of FIG. 5 and below.
  • Mean Oxycodone Released (mg)*
    Example 10 Example 11 Example 12 Example 13
    Intact 1.92 0.62 13.74 5.30
    24x Mortar 1.32 0.81 9.53 4.02
    & Pestle
    *Values are the mean of two repetitions of the test.

    3) In each of extractions a) to e) 400 mg of the multi particulates from one of Examples 10 to 13 were treated respectively as follows: the multi particulates were placed in the solvent indicated in a glass flask which was then heated (if heating is indicated) over a water bath. The flask was then subjected to shaking for the time indicated using a Stuart Scientific Flask Shaker Model SF1 set at 500 to 600 oscillations per minute. After extraction the amount of oxycodone dissolved was then determined by the method used in 1).
      • a) 15 minutes shaking in 10 ml water at room temperature;
      • b) heating for 5 minutes in 10 ml water at 50° C. followed by 15 minutes shaking;
      • e) heating for 5 minutes in 10 ml water at 75° C. followed by 15 minutes shaking.
      • d) heating for 5 minutes in 10 ml water at 100° C. followed by 15 minutes shaking.
      • e) 15 minutes shaking in 10 ml 40% ethanol at room temperature.
  • The test results are shown in the attached bar chart of FIG. 6 and below.
  • Example 10 Example 11 Example 12 Example 13
    40% ethanol 8.54 mg 28.26 mg 23.91 mg 31.85 mg
    room temp. (21.4% by wt) (71.7% by wt) (59.8% by wt) (79.6% by wt)
    15 min shake
    Water 1.22 mg  1.39 mg  3.47 mg  3.11 mg
    room temp.  (3.0% by wt)  (3.5% by wt)  (8.7% by wt)  (7.8% by wt)
    15 min shake
    Water 4.08 2.71 22.94 16.02
    50° C. for 5 min (10.2% by wt)  (6.8% by wt) (57.4% by wt) (40.1% by wt)
    15 min shake
    Water 5.34 5.28 37.09 35.78
    75° C. for 5 min (13.3% by wt) (13.2% by wt) (72.3% by wt) (89.5% by wt)
    15 min shake
    Water 6.60 33.18 37.92 35.36
    100° C. for 5 min (16.5% by wt) (82.9% by wt) (94.8% by wt) (88.4% by wt)
    15 min shake
  • Examples 15 to 24
  • Further Examples 15 to 24 are presented in Table 1 below.
  • Example 25 Alcohol Extraction Test and Dissolution Profiles
  • 400 mg of the multi particulates from one of Examples 15 to 21 were placed in 10 ml 40% ethanol at room temperature and subjected to shaking for 15 minutes using a Stuart Scientific Flask Shaker Model SF1 set at 500 to 600 oscillations per minute. After extraction the amount of oxycodone dissolved was then determined with detection by HPLC with UV at 206 mm wavelength. The extraction results are presented in Table 2 and FIG. 7. The dissolution profiles are determined using the Ph. Eur. Basket Apparatus at 100 rpm at 37° C. in 900 ml SGF optionally with 40% ethanol and detection by HPLC with UV at 206 nm wavelength. The dissolution results of Examples 15 to 21 in SGF with 40% ethanol are presented in Table 3 and FIG. 8. The dissolution profiles of Examples 15 to 21 in SGF are provided in Table 4 and of Examples 15 to 20 also in FIG. 9. The dissolution results in SGF with 40% ethanol and in SGF for Examples 22 to 24 are provided in Tables 5 and 6 and FIGS. 10 and 11, respectively.
  • TABLE 1
    Extruded Percent Content (w/w)
    Product Batch Oxycodone Ethylcellulose Kollidon Avicel Eudragit NE Stearyl Stearic Glycerol
    No. HCl N10 SR PH101 (from NE 40 D) Alcohol Acid Dibehenate Total (%)
    15 30 24.67 34.66 8.67 2 100
    16 30 30 32 6 2 100
    17 30 26 30 12 2 100
    18 30 22 40 6 2 100
    19 30 30 30 8 2 100
    20 30 20 36 12 2 100
    21 30 26 30 12 2 100
    22 30 35 24 9 2 100
    23 30 20 7 32 9 2 100
    24 30 27 32 9 2 100
  • TABLE 2
    Extraction Results for Examples 15 to 21 (40% ethanol
    at room temperature with shaking for 15 minutes)
    Mean1) Oxcodone Mean1) Percentage
    Example Recovered (mg) Oxycodone recovered (%)
    15 8.3 20.8
    16 7.7 19.3
    17 7.6 18.9
    18 7.5 18.8
    19 6.6 16.4
    20 7.1 17.8
    21 18.8 46.9
    1)Mean values are taken from two runs of the test for each of Examples 15 to 21
  • TABLE 3
    Dissolution Results for Examples
    15 to 21 in SGF with 40% ethanol
    % Oxycodone Released1)
    Time Ex. Ex. Ex. Ex. Ex. Ex. Ex.
    (hours) 15 16 17 18 19 20 21
    0 0. 0 0 0 0 0 0
    0.5 35.80 33.43 39.21 34.78 30.64 43.04 76.65
    1 54.08 50.60 59.54 52.55 47.51 66.22 97.08
    1.5 64.96 60.04 70.47 63.28 57.41 77.97 97.78
    2 73.42 68.88 78.38 71.80 65.13 85.89 97.70
    3 85.00 81.07 89.12 84.02 77.03 94.65 98.32
    1)Mean values are taken from two runs of the test for each of Examples 15 to 21
  • TABLE 4
    Dissolution Results for Examples 15 to 21 in SGF
    % Oxycodone Released
    Time Ex. Ex. Ex. Ex. Ex. Ex. Ex.
    (hours) 15 16 17 18 19 20 21
    0 0 0 0 0 0 0 0
    1 18.88 14.54 25.6 18.79 13.5 34.18 57.2
    2 26.43 20.46 38.3 27.25 19.52 51.44 86.51
    3 32.38 25.05 46.83 34.04 24.11 63.47 96.59
    4 37.36 28.92 54.31 39.56 28.16 72.51 98.77
    5 41.38 32.34 60.32 45.14 31.62 78.84 99.12
    6 45.47 35.46 67.94 48.82 34.54 83.79 99.01
    7 48.53 37.91 70.05 52.39 37.49 87.99 98.82
    8 51.68 40.86 74.41 56.22 40.14 91.46 99.03
    9 54.23 43.06 78.81 59.2 42.56 93.75 99.02
    10 56.51 44.83 80.81 61 44.76 95.73 98.9
    11 59.33 47.08 83.64 64.68 47.06 96.79 98.9
    12 61.14 48.89 85.61 68.2 48.74 97.92 99.14
    13 63.54 50.95 88.43 70.76 51.06 98.97 98.81
    14 65.14 52.43 89.84 71.7 52.54 98.41 98.53
    15 66.99 53.83 92.51 72.51 54.22 98.87 98.72
    16 68.67 55.13 94.51 77.03 55.7 98.38 98.9
    17 70.52 56.67 93.8 78.96 57.49 99.04 99.09
    18 73.18 58.21 96.81 79.48 58.71 98.91 98.89
    19 74.36 59.83 96 81.41 59.88 98.89 98.77
    20 74.78 60.41 96.94 82.94 61.24 98.65 98.67
    21 76.73 61.74 98.68 84.18 62.72 99.13 99.09
    22 75.76 61.26 97.7 83.56 64.19 99.17 98.81
    23 78.34 63.46 98.07 86.81 65.06 98.92 98.51
    24 79.53 64.69 98.16 86.55 66.13 99.07 98.66
  • TABLE 5
    Dissolution Results for Examples
    22 to 24 in SGF with 40% ethanol
    % Oxycodone Released1)
    Time (hours) Example 22 Example 23 Example 24
    0 0.00 0.00 0.00
    0.5 31.30 37.19 36.42
    1 45.54 55.37 52.68
    1.5 56.76 67.51 64.38
    2 64.17 75.64 72.97
    3 78.00 89.44 86.11
    4 86.70 95.30 92.40
    1)Mean values are taken from two runs of the test for each of Examples 22 to 24
  • TABLE 6
    Dissolution Results for Examples 22 to 24 in SGF
    % Oxycodone Released
    Time (hours) Example 22 Example 23 Example 24
    0 0.00 0.00 0.00
    1 13.74 26.51 17.78
    2 19.69 38.41 24.93
    3 23.65 46.41 30.09
    4 28.11 54.57 34.76
    5 31.24 60.16 38.05
    6 34.13 65.26 40.83
    7 37.03 68.13 44.12
    8 39.44 72.59 46.91
    9 42.10 75.59 48.75
    10 43.90 77.98 51.41
    11 46.19 80.38 53.71
    12 48.07 82.83 55.40
    13 50.14 86.18 57.33
    14 51.83 86.98 59.20
    15 53.49 88.72 60.43
    16 55.29 90.37 61.72
    17 57.05 91.94 64.22
    18 57.92 91.96 64.85
    19 59.25 93.98 65.38
    20 61.25 94.20 67.30
    21 61.78 95.19 68.81
    22 63.75 96.57 70.63
    23 64.30 96.91 71.91
    24 65.85 97.28 72.65

Claims (115)

1. Use of a sparingly water permeable thermoplastic polymer or a hydrophobic polymer as controlled release matrix material in the manufacture of an opioid controlled release matrix formulation to impart resistance to alcohol extraction of the opioid, wherein said formulation having the sparingly water permeable thermoplastic polymer or hydrophobic polymer as controlled release matrix material releases less opioid in an alcohol extraction test compared to the same formulation but with the sparingly water permeable thermoplastic polymer or hydrophobic polymer substituted entirely or partly by other matrix materials.
2. Use of a sparingly water permeable thermoplastic polymer as controlled release matrix material in the manufacture of an opioid salt controlled release matrix formulation to impart resistance to alcohol extraction of the opioid salt, wherein said formulation after 15 minutes shaking in 40% ethanol at room temperature releases less than 35% of opioid salt.
3. Use according to claim 2, wherein said formulation releases less than 30%, more preferred less than 25% of opioid salt, or from 15 to 25% opioid salt.
4. Use of a hydrophobic material as controlled release matrix material in the manufacture of an opioid salt controlled release matrix formulation to impart resistance to alcohol extraction of the opioid salt, wherein less than 25% of the opioid salt is released after 1 hour of in-vitro dissolution of a dosage form comprising said formulation in 900 ml of Simulated Gastric Fluid with 20% ethanol using USP Apparatus I (basket) operating at 100 rpm at 37° C.
5. Use of a hydrophobic material as controlled release matrix material in the manufacture of an opioid salt controlled release matrix formulation to impart resistance to alcohol extraction of the opioid salt, wherein less than 25% of the opioid salt is released after 1 hour of in-vitro dissolution of a dosage form comprising said formulation in 500 ml of Simulated Gastric Fluid with 20% ethanol using USP Apparatus I (basket) operating at 100 rpm at 37° C.
6. Use according claim 4 or 5, wherein less than 20% opioid salt, more preferred less than 10% opioid salt, even more preferred less than 5% opioid salt or between 10% and 25% opioid salt is released after 1 hour.
7. Use of a hydrophobic material as controlled release matrix material in the manufacture of an opioid salt controlled release matrix formulation to impart resistance to alcohol extraction of the opioid salt, wherein the ratio of the amount of opioid salt released after 1 hour of in-vitro dissolution of the dosage form comprising said formulation in 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37° C., to the amount of opioid salt released after 1 hour of in-vitro dissolution of the dosage form comprising said formulation in 900 ml of Simulated Gastric Fluid with 0% ethanol using an USP Apparatus I (basket) apparatus at 100 rpm at 37° C., is less than about 2:1.
8. Use of a hydrophobic material as controlled release matrix material in the manufacture of an opioid salt controlled release matrix formulation to impart resistance to alcohol extraction of the opioid salt, wherein the ratio of the amount of opioid salt released after 1 hour of in-vitro dissolution of the dosage form comprising said formulation in 500 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37° C., to the amount of opioid salt released after 1 hour of in-vitro dissolution of the dosage form comprising said formulation in 500 ml of Simulated Gastric Fluid with 0% ethanol using an USP Apparatus I (basket) apparatus at 100 rpm at 37° C., is less than about 2:1.
9. Use according to claim 7 or 8, wherein the ratio is less than 1.5:1, preferably less than 1:1.
10. Use according to any one of the preceding claims, wherein the hydrophobic material or the sparingly permeable thermoplastic polymer is an alkyl cellulose.
11. Use according to claim 10, wherein the alkyl cellulose is ethyl cellulose.
12. Use according to any one of the preceding claims, wherein the opioid salt is selected from opioid agonists, opioid antagonists in combination with opioid agonists the combination providing an analgesic effect, and mixed opioid agonist/antagonists partial opioid agonists or mixtures thereof in the form of the pharmaceutically acceptable salts thereof.
13. Use according to any one of the preceding claims, wherein the opioid salt is selected from alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diarnorphone, dihydro codeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydroco done, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papavereturn, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, in the form of pharmaceutically acceptable salts thereof; and mixtures of any of the foregoing, and the like, preferably from pharmaceutically acceptable salts of any of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone.
14. Use according to any one of the preceding claims, wherein the opioid salt is a combination of an opioid agonist salt and an opioid antagonist salt, the combination providing an analgesic effect, wherein the opioid antagonist is selected form the group of naloxone, naltrexone and nalorphine in the form of pharmaceutically acceptable salts thereof.
15. Use according to claims 10 to 14, wherein the alkyl cellulose, preferably ethyl cellulose, is used in an amount from 5 to 60% (by wt) of the matrix formulation, preferably from 10 to 50% (by wt), most preferably from 20 to 45% (by wt) of the matrix formulation, or in an amount of at least 40% (by wt), at least 45% (by wt), at least 50% (by wt), at least 55% (by wt) or at least 60% (by wt) of the matrix formulation.
16. Use according to any one of the preceding claims, wherein the ethyl cellulose is combined with at least a second controlled release matrix material selected from a polymethacrylate polymer, preferably a neutral water-insoluble poly (ethyl acrylate, methyl methacrylate) copolymer.
17. Use according to claim 16, wherein the polymethacrylate polymer, preferably the neutral water-insoluble poly(ethyl acrylate, methyl acrylate) copolymer is used in an amount of 5% to 66% (by wt), preferably 15% to 50% (by wt), more preferred 20% to 45% (by wt) and most preferred 25% to 45% (by wt) or in a weight amount of at least 5% (by wt), at least 10% (by wt), at least 15% (by wt), at least 20% (by wt) or at least 25% (by wt) of the matrix formulation.
18. Use according to claims 10 to 17, wherein the opioid salt is oxycodone hydrochloride or hydromorphone hydrochloride.
19. Use according to any one of the previous claims, wherein at least one binder, preferably hydroxy alkyl cellulose, is included in the matrix formulation.
20. Use according to claims 10 to 14, wherein the amount of the alkyl cellulose, preferably ethyl cellulose, is less than 20% (by wt), preferably less than 15% (by wt), most preferred less than 10% (by wt) of the matrix formulation.
21. Use according to claim 20, wherein the alkylcellulose, preferable ethylcellulose is combined with at least one plasticizer or second controlled release matrix material selected from C12 to C36 aliphatic alcohols or corresponding aliphatic acids, preferably stearyl alcohol, cetyl alcohol, cetostearyl alcohol, stearic acid or palmitic acid or mixtures thereof.
22. Use according to claim 21, wherein the alkyl cellulose, preferably the amount of C12 to C36 aliphatic alcohol is at least 5%, more preferred at least 10% (by wt), more preferred at least 15% (by wt) and most preferred 20% to 25% (by wt) of the matrix formulation.
23. Use according to claims 20 to 22, wherein the opioid salt is a mixture of oxycodone hydrochloride and naloxone hydrochloride in an amount ratio of 2:1.
24. Use according to claims 19 to 23, wherein the matrix formulation does not comprise a neutral water-insoluble poly (ethyl acrylate methyl acrylate) copolymer.
25. Use according to any one of the preceding claims, wherein the matrix formulation does not comprise a poly(meth)acrylate trimethylammoniummethylacrylate chloride copolymer.
26. Use according to any one of the preceding claims, wherein the matrix formulations is prepared in a melt extrusion process.
27. Use according to any of the preceding claims wherein the controlled release matrix formulations after 15 minutes shaking in water at room temperature releases less than 15%, less than 10% of opioid salt, preferably less than 7.5% opioid salt, more preferably less than 5% opioid salt.
28. Use according to any of the preceding claims wherein the controlled release matrix formulation after 5 minutes standing in water at 50° C. followed by 15 minutes shaking at the same temperature releases less than 20% opioid salt, preferably less than 15% opioid salt, more preferably less than 12% opioid salt.
29. Use according to any of the preceding claims wherein the controlled release matrix formulation after 5 minutes standing at 75° C. followed by 15 minutes shaking at the same temperature releases less than 25% of opioid salt, preferably less than 20% of opioid salt, more preferably less than 15% of opioid salt.
30. Use according to any of the preceding claims wherein the controlled release matrix formulation after 5 minutes standing at 100° C. followed by 15 minutes shaking at the same temperature releases less than 30% opioid salt, preferably less than 25% opioid salt, more preferably less than 20% opioid salts.
31. Use according to any one of the preceding claims wherein the ratio of the weight % amount of the opioid salt released at 50° C., 120 minutes shaking of the controlled release matrix formulation to the weight % amount of opioid salt released at RT 120 minutes shaking of the controlled release matrix formulation is 1.2 or less, preferably 1 or less or 0.9 or less.
32. Use according to any one of the preceding claims wherein the ratio of the weight % amount of the opioid salt released at 75° C., 15 minutes shaking of the controlled release matrix formulation to the weight % amount of opioid analgesic released at RT 15 minutes shaking of the controlled release matrix formulation is 1.2 or less, preferably 1 or less or 0.9 or less.
33. Use according to any one of the preceding claims wherein the ratio of the weight % amount of the opioid salt released at 100° C., 15 minutes shaking of the controlled release matrix formulation to the weight % amount of opioid salt released at RT 15 minutes shaking of the controlled release matrix formulation is 1.3 or less, preferably 1.2 or less or 0.9 or less.
34. Use according to any one of the preceding claims wherein the ratio of the weight % amount of the opioid salt released at 100° C., 120 minutes shaking of the controlled release matrix formulation to the weight % amount of opioid salt released at RT 120 minutes shaking of the controlled release matrix formulation is less than 2, preferably 1.5 or less or 1 or less or 0.9 or less.
35. Use according to any one of the preceding claims wherein the controlled release matrix formulation after grinding in a mortar and pestle with 24 rotations of the pestle and extracting in 900 ml water at 37° C. for 45 minutes less than 12.5% opioid salt, preferably less than 10% opioid salt, more preferably less than 7.5% opioid salt are released.
36. Use according to any one of the preceding claims wherein the controlled release matrix formulation after crushing between two spoons or in a pill crusher and extracting in 2 ml water heated to boiling on a spoon less than 27.5% opioid salt, preferably less than 15% opioid salt, more preferably less than 5% opioid salt are released.
37. A controlled release dosage form comprising:
a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material;
wherein less than 25% of the opioid salt is released after 1 hour of in-vitro dissolution of the dosage form in 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.°.
38. A controlled release dosage form comprising:
a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material;
wherein less than 25% of the opioid salt is released after 1 hour of in-vitro dissolution of the dosage form in 500 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.°.
39. The dosage form of claim 37 or 38 comprising
a plurality of matrices comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material.
40. The dosage form of claim 37 or 38 comprising
a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a pharmaceutically acceptable excipient; and
a layer comprising a controlled release material disposed about the matrix.
41. The dosage form of claim 37 or 38 comprising
a plurality of matrices comprising a pharmaceutically acceptable salt of an opioid analgesic in a pharmaceutically acceptable excipient; and
a layer comprising a controlled release material disposed about each of the matrices.
42. The dosage form of any of claims 37 to 41, wherein the controlled release material is a hydrophobic material.
43. The dosage form of claim 42, wherein the hydrophobic material is ethylcellulose.
44. The dosage form of claim 43, wherein ethylcellulose in a weight amount of at least 40%, at least 45%, at least 50%, at least 55% or at least 60% of the matrix or matrices.
45. The dosage form of claim 44, wherein the ethylcellulose is in a weight amount of at most 70%, at most 80% or at most 90% of the matrix or matrices.
46. The dosage form of claim 44, wherein the controlled release material further comprises a polymethacrylate polymer in a weight amount of at least 5%, at least 10%, at least 15%, at least 20% or at least 25% of the matrix or matrices.
47. The dosage form of claim 46, wherein the polymethacrylate polymer is in a weight amount of at most 25% or at most 30%, or at most 35% of the matrix or matrices.
48. The dosage form according to claims 37 to 47, wherein the matrix or matrices do not contain a water-insoluble neutral poly (ethylacrylate methyl methacrylate) copolymer.
49. The dosage form of any of claims 37 to 38, wherein the dosage form further comprises a binder in a weight amount of at least 1%, at least 3%, or at least 5% of the matrix or matrices.
50. The dosage form of claim 49, wherein the binder is in a weight amount of at most 7%, or at most 10% of the matrix or matrices.
51. The dosage form of claim 49 or 50, wherein the binder is a hydroxyalkylcellulose.
52. The dosage form of any of claims 37 to 51, wherein the dosage form further comprises a plasticizer in a weight amount of at least 5%, at least 15%, or at least 25% of the matrix or matrices.
53. The dosage form of claim 52, wherein the plasticizer is in a weight amount of at most 30%, or at most 40% of the matrix or matrices.
54. The dosage form of claim 52 or 53, wherein the plasticizer has a melting point of at least 80° C.
55. The dosage form of claim 54, wherein the plasticizer is hydrogenated castor oil.
56. The dosage form of claim 42, wherein the hydrophobic material is an enteric polymer.
57. The dosage form of any of claims 37-41, wherein the matrix or matrices are extruded.
58. The dosage form of claim 37 or 39, wherein the matrix is a compressed granulation.
59. The dosage form of any of claims 37 to 41, wherein the dosage form releases less than 20% opioid salt after 1 hour of in-vitro dissolution of the dosage form in 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.°.
60. The dosage form of any of claims 37 to 41, wherein the dosage form releases more than 5% or more than 10% opioid salt after 1 hour of in-vitro dissolution of the dosage form in 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.°.
61. The dosage form of any of claims 37 to 60, wherein the opioid salt is hydromorphone hydrochloride, and the dosage form comprises:
2 mg hydromorphone hydrochloride,
4 mg hydromorphone hydrochloride,
8 mg hydromorphone hydrochloride,
12 mg hydromorphone hydrochloride,
16 mg hydromorphone hydrochloride,
24 mg hydromorphone hydrochloride,
32 mg hydromorphone hydrochloride,
48 mg hydromorphone hydrochloride or
64 mg hydromorphone hydrochloride.
62. The dosage form of any of claims 37 to 60, wherein the opioid salt is oxycodone hydrochloride and the dosage form comprises:
5 mg oxycodone hydrochloride,
10 mg oxycodone hydrochloride,
15 mg oxycodone hydrochloride
20 mg oxycodone hydrochloride,
30 mg oxycodone hydrochloride,
40 mg oxycodone hydrochloride,
45 mg oxycodone hydrochloride
60 mg oxycodone hydrochloride,
80 mg oxycodone hydrochloride,
90 mg oxycodone hydrochloride
120 mg oxycodone hydrochloride or
160 mg oxycodone hydrochloride
63. A method of treating pain comprising administering to a patient in need thereof a
dosage form of any of claims 37 to 62.
64. A method of deterring abuse of an opioid agonist comprising preparing a
dosage form according to any of claims 37 to 62.
65. A method of manufacturing a controlled release dosage form of any of claims 37 to 62 comprising extruding the pharmaceutically acceptable salt of the opioid analgesic and the controlled release material.
66. The method of claim 65, comprising cutting the extrudate into a plurality of particles, optionally compressing the particles into a tablet, or filling the particles into a pharmaceutically acceptable capsule.
67. A controlled release dosage form comprising an opioid analgesic salt and a controlled release material:
wherein the ratio of the amount of opioid analgesic salt released after 1 hour of in-vitro dissolution of the dosage form in 500 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of opioid analgesic salt released after 1 hour of in-vitro dissolution of the dosage form in 500 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is less than about 2:1.
68. A controlled release dosage form comprising an opioid analgesic salt and a controlled release material:
wherein the ratio of the amount of opioid analgesic salt released after 1 hour of in-vitro dissolution of the dosage form in 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of opioid analgesic salt released after 1 hour of in-vitro dissolution of the dosage form in 900 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is less than about 2:1.
69. The dosage form of claim 67 or 68, comprising a matrix comprising the opioid analgesic salt and the controlled release material.
70. The dosage form of claim 67 or 68, comprising a plurality of matrices comprising the opioid analgesic salt and the controlled release material.
71. A controlled release dosage form of claim 69 or 70, wherein the opioid analgesic salt is not a combination of oxycodone salt and naloxone salt wherein the matrix comprises ethyl cellulose and stearyl alcohol.
72. The dosage form of claim 67 or 68, comprising a matrix comprising the opioid analgesic salt and a pharmaceutically acceptable excipient; and a layer comprising a controlled release material disposed about the matrix.
73. The dosage form of claim 67 or 68, comprising a plurality of matrices comprising the opioid analgesic and a pharmaceutically acceptable excipient; and a layer comprising a controlled release material disposed about each of the matrices.
74. The dosage form of any of claims 67 to 73, wherein the controlled release material is a hydrophobic material.
75. The dosage form of claim 74, wherein the hydrophobic material is ethylcellulose.
76. The dosage form of claim 75, wherein ethylcellulose in a weight amount of at least 40%, at least 45%, at least 50%, at least 55% or at least 60% of the matrix or matrices.
77. The dosage form of claim 76, wherein the ethylcellulose is in a weight amount of at most 70%, at most 80% or at most 90% of the matrix or matrices.
78. The dosage form of claim 77, wherein the controlled release material further comprises a polymethacrylate polymer in a weight amount of at least 5%, at least 10%, at least 15%, at least 20% or at least 25% of the matrix or matrices.
79. The dosage form of claim 78, wherein the polymethacrylate polymer is in a weight amount of at most 30%, or at most 35% of the matrix or matrices.
80. The dosage form of any of claims 37 to 79, wherein the dosage form further comprises a binder in a weight amount of at least 1%, at least 3%, or at least 5% of the matrix or matrices.
81. The dosage form of claim 80, wherein the binder is in a weight amount of at most 7%, or at most 10% of the matrix or matrices.
82. The dosage form of claim 80 or 81, wherein the binder is a hydroxyalkylcellulose.
83. The dosage form of any of claims 37 to 82, wherein the dosage form further comprises a plasticizer in a weight amount of at least 5%, at least 15%, or at least 25% of the matrix or matrices.
84. The dosage form of claim 83, wherein the plasticizer is in a weight amount of at most 30%, or at most 40% of the matrix or matrices.
85. The dosage form of claim 83 or 84, wherein the plasticizer which has a melting point of at least 80° C.
86. The dosage form of claim 85, wherein the plasticizer is hydrogenated castor oil.
87. The dosage form of claim 74 wherein the hydrophobic material is an enteric polymer.
88. The dosage form of any of claims 67 to 73 wherein the matrix or matrices are extruded.
89. The dosage form of claims 67 to 73, wherein the matrix is a compressed granulation.
90. The dosage form of any of claims 67 to 73, wherein the ratio of the amount of opioid analgesic released after 1 hour of in-vitro dissolution of the dosage form in 500 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of opioid analgesic released after 1 hour of in-vitro dissolution of the dosage form in 500 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is less than about 1.5:1 or less than about 1:1.
91. The dosage form of any of claims 37 to 90, wherein the opioid salt is hydromorphone hydrochloride, and comprises:
2 mg hydromorphone hydrochloride,
4 mg hydromorphone hydrochloride,
8 mg hydromorphone hydrochloride,
12 mg hydromorphone hydrochloride,
16 mg hydromorphone hydrochloride,
24 mg hydromorphone hydrochloride,
32 mg hydromorphone hydrochloride,
48 mg hydromorphone hydrochloride, or
64 mg hydromorphone hydrochloride.
92. The dosage form of any of claims 37 to 90, wherein the opioid salt is oxycodone hydrochloride, and comprises:
5 mg oxycodone hydrochloride,
10 mg oxycodone hydrochloride,
15 mg oxycodone hydrochloride,
20 mg oxycodone hydrochloride,
30 mg oxycodone hydrochloride,
40 mg oxycodone hydrochloride,
45 mg oxycodone hydrochloride,
60 mg oxycodone hydrochloride,
80 mg oxycodone hydrochloride,
90 mg oxycodone hydrochloride,
120 mg oxycodone hydrochloride, or
160 mg oxycodone hydrochloride.
93. A controlled release dosage form comprising a plurality of matrices comprising a therapeutically effective amount of a pharmaceutically acceptable salt of hydromorphone dispersed in a controlled release material;
wherein the ratio of the amount of the pharmaceutically acceptable salt of hydromorphone released after 1 hour of in-vitro dissolution of the dosage form in 500 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° to the amount of a pharmaceutically acceptable salt of hydromorphone released after 1 hour of in-vitro dissolution of the dosage form in 500 ml of Simulated Gastric Fluid with 0% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C.° is less than about 2:1.
94. The dosage form of claim 93 comprising a plurality of extruded matrices comprising a therapeutically effective amount of a pharmaceutically acceptable salt of hydromorphone dispersed in an alkylcellulose.
95. The dosage form of claim 93 comprising a plurality of extruded matrices comprising a therapeutically effective amount of a pharmaceutically acceptable salt of hydromorphone dispersed in an ethylcellulose.
96. The dosage form of claim 93 comprising a plurality of extruded matrices comprising a therapeutically effective amount of a pharmaceutically acceptable salt of hydromorphone dispersed in an alkylcellulose, the alkylcellulose being at least 50%, w/w of the matrices.
97. The dosage form of claim 93 comprising a plurality of extruded matrices consisting essentially of a pharmaceutically acceptable salt of hydromorphone dispersed in an alkylcellulose.
98. The dosage form of claim 93 comprising a plurality of extruded matrices consisting essentially of a pharmaceutically acceptable salt of hydromorphone dispersed in an alkylcellulose, an optional binder, and an optional plasticizer.
99. The dosage form of claim 93 comprising a plurality of extruded matrices comprising a pharmaceutically acceptable salt of hydromorphone dispersed in an alkylcellulose, wherein the matrices do not comprise an acrylic polymer.
100. The dosage form of any of claims 27 to 89 comprising a controlled release matrix formulation which does not contain more than 15% (by wt) preferably more than 20% (by wt) C12 to C36 aliphatic alcohol selected from the group consisting of stearyl alcohol, cetyl alcohol and cetostearyl alcohol.
101. The dosage form according to any of the preceding claims wherein the dosage form after 15 minutes shaking in water at room temperature releases less than 15%, less than 10% of opioid salt, preferably less than 7.5% opioid salt, more preferably less than 5% opioid salt.
102. The dosage form according to any of the preceding claims wherein the dosage form after 5 minutes standing in water at 50° C. followed by 15 minutes shaking at the same temperature releases less than 20% opioid salt, preferably less than 15% opioid salt, more preferably less than 12% opioid salt.
103. The dosage form according to any of the preceding claims wherein the dosage form after 5 minutes standing at 75° C. followed by 15 minutes shaking at the same temperature releases less than 25% of opioid salt, preferably less than 20% of opioid salt, more preferably less than 15% of opioid salt.
104. The dosage form according to any of the preceding claims wherein the dosage form after 5 minutes standing at 100° C. followed by 15 minutes shaking at the same temperature releases less than 30% opioid salt, preferably less than 25% opioid salt, more preferably less than 20% opioid sal.
105. The dosage form according to any one of the preceding claims wherein the ratio of the weight % amount of the opioid salt released at 50° C., 120 minutes shaking of the dosage form to the weight % amount of opioid salt released at RT 120 minutes shaking of the dosage form is 1.2 or less, preferably 1 or less or 0.9 or less.
106. The dosage form according to any one of the preceding claims wherein the ratio of the weight % amount of the opioid salt released at 75° C., 15 minutes shaking of the dosage form to the weight % amount of opioid analgesic released at RT 15 minutes shaking of the dosage form is 1.2 or less, preferably 1 or less or 0.9 or less.
107. The dosage form according to any one of the preceding claims wherein the ratio of the weight % amount of the opioid salt released at 100° C., 15 minutes shaking of the dosage form to the weight % amount of opioid salt released at RT 15 minutes shaking of the dosage form is 1.3 or less, preferably 1.2 or less or 0.9 or less.
108. The dosage form according to any one of the preceding claims wherein the ratio of the weight % amount of the opioid salt released at 100° C., 120 minutes shaking of the dosage form to the weight % amount of opioid salt released at RT 120 minutes shaking of the dosage form is less than 2, preferably 1.5 or less, 1 or less or 0.9 or less.
109. The dosage form according to any one of the preceding claims wherein after grinding in a mortar and pestle with 24 rotations of the pestle and extracting in 900 ml water at 37° C. for 45 minutes less than 12.5% opioid salt, preferably less than 10% opioid salt, more preferably less than 7.5% opioid salt are released.
110. Use according to any one of the preceding claims wherein after crushing between two spoons or in a pill crusher and extracting in 2 ml water heated to boiling on a spoon less than 27.5% opioid salt, preferably less than 15% opioid salt, more preferably less than 5% opioid salt are released.
111. A method of treating pain comprising administering to a patient in need thereof a dosage form of any of claims 37 to 109.
112. Use of a dosage form according to claims 37 to 109 in the manufacture of a medicament for the treatment of pain.
113. A method of deterring abuse of an opioid agonist comprising preparing a dosage form according to any of claims 37 to 109.
114. A method of manufacturing a controlled release dosage form of any of claims 69 to 109 comprising extruding the pharmaceutically acceptable salt of the opioid analgesic and the controlled release material.
115. The method of claim 114, comprising cutting the extrudate into a plurality of particles, optionally comprising compressing the particles into a tablet or filling the particles into a pharmaceutically acceptable capsule.
US13/157,093 2004-02-12 2011-06-09 Alcohol resistant dosage forms Abandoned US20120141583A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/050014 2004-02-12
GB0403100A GB0403100D0 (en) 2004-02-12 2004-02-12 Particulates
GB0403100.1 2004-02-12
GBGB0501638.1A GB0501638D0 (en) 2005-01-28 2005-01-28 Particulates
GB0501638.1 2005-01-28
PCT/GB2005/050014 WO2005079760A1 (en) 2004-02-12 2005-02-11 Particulates
PCT/EP2006/000727 WO2006079550A2 (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
US57477807A true 2007-03-06 2007-03-06
US13/157,093 US20120141583A1 (en) 2004-02-12 2011-06-09 Alcohol resistant dosage forms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/157,093 US20120141583A1 (en) 2004-02-12 2011-06-09 Alcohol resistant dosage forms
US15/367,095 US20170079923A1 (en) 2004-02-12 2016-12-01 Alcohol resistant dosage forms
US15/886,659 US20180153812A1 (en) 2004-02-12 2018-02-01 Alcohol resistant dosage forms

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2006/000727 Continuation WO2006079550A2 (en) 2004-02-12 2006-01-27 Alcohol resistant dosage forms
US57477807A Continuation 2007-03-06 2007-03-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/367,095 Continuation US20170079923A1 (en) 2004-02-12 2016-12-01 Alcohol resistant dosage forms

Publications (1)

Publication Number Publication Date
US20120141583A1 true US20120141583A1 (en) 2012-06-07

Family

ID=34889127

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/588,978 Active 2027-10-01 US8920836B2 (en) 2004-02-12 2005-02-11 Particulates
US13/157,093 Abandoned US20120141583A1 (en) 2004-02-12 2011-06-09 Alcohol resistant dosage forms
US14/547,874 Abandoned US20150148366A1 (en) 2004-02-12 2014-11-19 Particulates
US15/367,095 Abandoned US20170079923A1 (en) 2004-02-12 2016-12-01 Alcohol resistant dosage forms
US15/886,659 Pending US20180153812A1 (en) 2004-02-12 2018-02-01 Alcohol resistant dosage forms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/588,978 Active 2027-10-01 US8920836B2 (en) 2004-02-12 2005-02-11 Particulates

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/547,874 Abandoned US20150148366A1 (en) 2004-02-12 2014-11-19 Particulates
US15/367,095 Abandoned US20170079923A1 (en) 2004-02-12 2016-12-01 Alcohol resistant dosage forms
US15/886,659 Pending US20180153812A1 (en) 2004-02-12 2018-02-01 Alcohol resistant dosage forms

Country Status (16)

Country Link
US (5) US8920836B2 (en)
EP (1) EP1729731A1 (en)
JP (2) JP5122823B2 (en)
KR (1) KR101189038B1 (en)
AR (1) AR047540A1 (en)
AU (1) AU2005215239B2 (en)
BR (1) BRPI0507683A8 (en)
CA (1) CA2555423C (en)
EA (1) EA200601468A1 (en)
IL (1) IL177313A (en)
NO (1) NO20064094L (en)
NZ (1) NZ548962A (en)
PE (2) PE18982009A1 (en)
TW (1) TWI350762B (en)
UY (1) UY28744A1 (en)
WO (1) WO2005079760A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070298103A1 (en) * 2004-02-12 2007-12-27 Euro-Celtique S.A. Particulates
US20090029170A1 (en) * 2004-02-12 2009-01-29 Geoffrey Gerard Hayes Extrusion
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9216176B2 (en) 2006-09-15 2015-12-22 Cima Labs Inc. Abuse resistant drug formulation
EP2939663A4 (en) * 2012-12-31 2016-09-21 Samyang Biopharmaceuticals Melt extruded pharmaceutical composition for controlling release, and medicine for oral administration including same
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9730885B2 (en) 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9814679B2 (en) 2009-06-05 2017-11-14 Euro-Celtique S.A. Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2266564T3 (en) 1997-12-22 2013-06-03 Euro Celtique Sa A pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
TWI334779B (en) 2002-04-05 2010-12-21 Euro Celtique Sa Pharmaceutical preparation containing oxycodone and naloxone
CA2480826C (en) 2002-04-09 2012-02-07 Flamel Technologies Oral pharmaceutical formulation in the form of microcapsule aqueous suspension allowing modified release of active ingredient(s)
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
MX2008009267A (en) * 2006-01-21 2008-10-09 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse.
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
FR2901478B1 (en) * 2006-05-24 2015-06-05 Flamel Tech Sa oral pharmaceutical form multimicroparticulate SUSTAINED RELEASE
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with impeded abuse
SI2180882T1 (en) 2007-10-19 2013-05-31 Otsuka Pharmaceutical Co., Ltd. Solid matrix pharmaceutical preparation
TW200950776A (en) * 2008-01-24 2009-12-16 Abbott Gmbh & Co Kg Abuse resistant melt extruded formulation having reduced alcohol interaction
JP2011511782A (en) 2008-02-12 2011-04-14 アボット・ラボラトリーズAbbott Laboratories Extended release hydrocodone acetaminophen and its related methods and applications
WO2010017056A1 (en) * 2008-08-07 2010-02-11 Merck & Co., Inc. Orally administered solid formulations containing a hydrophobic drug and tpgs
MX2011001864A (en) * 2008-08-20 2011-06-20 Univ Texas Hot-melt extrusion of modified release multi-particulates.
FR2938431B1 (en) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma New composition based on gamma-hydroxybutyric acid
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
FR2949062B1 (en) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma New pharmaceutical formulations against the misuse of drugs
FR2949061B1 (en) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma floating microgranules
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
CN103002881B (en) 2010-05-10 2015-09-02 欧洲凯尔特公司 Compositions containing the active agent particles and the additional active agent
EP2568967B1 (en) 2010-05-10 2018-10-24 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
BR112012028788A2 (en) 2010-05-10 2016-07-19 Euro Celtique Sa manufacturing granules without active
JP5973347B2 (en) * 2010-08-31 2016-08-23 協和発酵キリン株式会社 Orally disintegrating tablet
US9278052B2 (en) 2010-11-04 2016-03-08 Abbvie Inc. Method for producing monolithic tablets
US20120202838A1 (en) 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
JP5832645B2 (en) * 2011-06-17 2015-12-16 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングEvonik Roehm GmbH Pharmaceutical dosage form or a nutritional supplement coating composition suitable for the form
EP2768537B1 (en) * 2011-10-18 2019-02-20 Purdue Pharma LP Acrylic polymer formulations
CN104394851B (en) * 2012-04-18 2017-12-01 格吕伦塔尔有限公司 Dose anti-tampering and anti - dumping pharmaceutical dosage forms
JP2016525138A (en) 2013-07-23 2016-08-22 ユーロ−セルティーク エス.エイ. The combination of oxycodone and naloxone for use in the treatment of pain in patients suffering from diseases increase the risk for diseases and / or Enterobacteriaceae migration results in pain and intestinal Disconnect bio cis
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EA030310B1 (en) 2013-11-13 2018-07-31 Эро-Селтик С.А. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2017172406A1 (en) * 2016-03-31 2017-10-05 Mallinckrodt Llc Extended release, abuse deterrent dosage forms
FR3070390A1 (en) * 2017-08-25 2019-03-01 Eleonor Composition comprising at least one alkaloid of protoberberine and process for its manufacturing
WO2019073028A1 (en) 2017-10-13 2019-04-18 Grünenthal GmbH Modified release abuse deterrent dosage forms

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080134A (en) * 1975-09-23 1978-03-21 Mobil Oil Corporation Apparatus for pelletizing plastic material
GB1603640A (en) * 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
DE3612212A1 (en) * 1986-04-11 1987-10-15 Basf Ag shaping process for the preparation of solid pharmaceutical
US4800087A (en) 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JPH07112697B2 (en) 1989-08-18 1995-12-06 三菱レイヨン株式会社 Preparation of the thermoplastic resin spherical particles
US5085815A (en) * 1989-12-26 1992-02-04 Exxon Chemical Patents Inc. Process of recovering and conveying shaped polymer extrudate
FR2663818B1 (en) 1990-06-29 1993-07-09 Rhone Poulenc Nutrition Animal Process for the preparation of granules of active ingredients by extrusion.
ZA9109510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
DE4138513A1 (en) * 1991-11-23 1993-05-27 Basf Ag A solid pharmaceutical sustained-release form
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
JP2616252B2 (en) 1992-10-16 1997-06-04 日本新薬株式会社 Preparation of the wax matrix
US5500161A (en) * 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE4413350A1 (en) * 1994-04-18 1995-10-19 Basf Ag Slow-release matrix pellets, and methods for their preparation
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19504119C2 (en) * 1995-02-08 2000-07-13 S Rockstedt Gmbh Maschf At the exit of an extruder mounted nozzle head
DE69726729T2 (en) * 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungicidal agents with improved bioavailability
JP2002511777A (en) 1996-10-28 2002-04-16 ゼネラル ミルズ,インコーポレイテッド Embedding and encapsulation regulating release particles
US6013272A (en) * 1996-12-19 2000-01-11 Valent U.S.A. Corporation Chemically stable, insecticidally active phosphoroamidothioate pellet compositions and methods for their manufacture
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
BR0013825A (en) * 1999-08-31 2002-07-23 Gruenenthal Chemie tramadol presentation forms
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
SI2092936T1 (en) 2000-02-08 2013-07-31 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
DE10015479A1 (en) * 2000-03-29 2001-10-11 Basf Ag Solid oral dosage forms with delayed release of active ingredient and high mechanical stability
US6712789B1 (en) 2000-07-13 2004-03-30 Medamicus, Inc. Introducer having a movable valve assembly with removable side port
SE0100200D0 (en) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
KR20120028993A (en) * 2001-05-02 2012-03-23 유로-셀티크 소시에떼 아노뉨 Once-a-day oxycodone formulations
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7691430B2 (en) * 2001-11-07 2010-04-06 Medwell Foods, Inc. Food material technology with controllable functional characteristics and industrial process applications, and the resulting fabricated foods
TWI334779B (en) 2002-04-05 2010-12-21 Euro Celtique Sa Pharmaceutical preparation containing oxycodone and naloxone
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cushman, Alcohol and Opioids: Possible Interactions of Clinical Importance", 1997, Advances in Alcohol & Substance Abuse, Vol 6(3), pages 33-43 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US8920836B2 (en) 2004-02-12 2014-12-30 Euro-Celtique S.A. Particulates
US9603802B2 (en) 2004-02-12 2017-03-28 Euro-Celtique S.A. Extrusion
US20090029170A1 (en) * 2004-02-12 2009-01-29 Geoffrey Gerard Hayes Extrusion
US20070298103A1 (en) * 2004-02-12 2007-12-27 Euro-Celtique S.A. Particulates
US9216176B2 (en) 2006-09-15 2015-12-22 Cima Labs Inc. Abuse resistant drug formulation
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9814679B2 (en) 2009-06-05 2017-11-14 Euro-Celtique S.A. Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9730885B2 (en) 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US10143659B2 (en) 2012-12-31 2018-12-04 Samyang Biopharmaceutical Corporation Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same
EP2939663A4 (en) * 2012-12-31 2016-09-21 Samyang Biopharmaceuticals Melt extruded pharmaceutical composition for controlling release, and medicine for oral administration including same
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9486451B2 (en) 2014-09-12 2016-11-08 Recro Gainesville Llc Abuse resistant pharmaceutical compositions
US10092559B2 (en) 2014-09-12 2018-10-09 Recro Gainesville Llc Abuse resistant pharmaceutical compositions
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9713611B2 (en) 2014-09-12 2017-07-25 Recro Gainesville, LLC Abuse resistant pharmaceutical compositions
US9452163B2 (en) 2014-09-12 2016-09-27 Recro Gainesville Llc Abuse resistant pharmaceutical compositions
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms

Also Published As

Publication number Publication date
US20070298103A1 (en) 2007-12-27
US20170079923A1 (en) 2017-03-23
WO2005079760A1 (en) 2005-09-01
KR20070029673A (en) 2007-03-14
EP1729731A1 (en) 2006-12-13
US20150148366A1 (en) 2015-05-28
BRPI0507683A (en) 2007-07-17
AU2005215239B2 (en) 2011-03-24
AR047540A1 (en) 2006-01-25
US8920836B2 (en) 2014-12-30
CA2555423A1 (en) 2005-09-01
JP5122823B2 (en) 2013-01-16
JP5746664B2 (en) 2015-07-08
KR101189038B1 (en) 2012-10-08
PE07752005A1 (en) 2005-11-28
AU2005215239A1 (en) 2005-09-01
TWI350762B (en) 2011-10-21
PE18982009A1 (en) 2009-12-31
NZ548962A (en) 2010-08-27
NO20064094L (en) 2006-11-10
JP2007522196A (en) 2007-08-09
EA200601468A1 (en) 2007-02-27
TW200529888A (en) 2005-09-16
IL177313A (en) 2014-11-30
IL177313D0 (en) 2006-12-10
CA2555423C (en) 2018-07-24
UY28744A1 (en) 2005-08-31
US20180153812A1 (en) 2018-06-07
JP2012193186A (en) 2012-10-11
BRPI0507683A8 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
AU2002323032B2 (en) Opioid agonist formulations with releasable and sequestered antagonist
JP6403742B2 (en) Resistant oral opioid agonist formulation external pressure
EP2011485B1 (en) Once-a-day oxycodone formulations
US10201502B2 (en) Tamper-resistant tablet providing immediate drug release
EP1623703B1 (en) Controlled release hydrocodone formulations
AU2013203493B2 (en) Tamper resistant immediate release formulations
JP5926738B2 (en) Dosage form
US20020164373A1 (en) Opioid sustained-released formulation
JP3186064B2 (en) Orally administrable opioid formulation by melt extrusion
CA2822769C (en) Tamper resistant solid oral dosage forms
AU2007209290B2 (en) Tamper resistant dosage forms
ES2713957T3 (en) Pharmaceutical form with inviolable closure comprising a matrix and melt extruded particles comprising a drug
US20040176402A1 (en) Controlled-release compositions containing opioid agonist and antagonist
AU2007287341B2 (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
US8465774B2 (en) Sequestered antagonist formulations
JP6282261B2 (en) Preventing unauthorized use and excess emission preventing pharmaceutical dosage forms
CA2737257C (en) Pharmaceutical dosage forms comprising poly(.epsilon.-caprolactone)
DK2826467T3 (en) Enclosed, tamper-resistant dosage forms for sustained release
DK2269579T3 (en) Manipulation Safe products for administration of opioids
JP4997109B2 (en) Dose proportional steady state cave and steady state auc, as well as opioid dosage form with small single dose cmax than dose proportional
EP2688556B1 (en) Controlled release pharmaceutical dosage forms
DK1586311T3 (en) Melt extrusion of spherical multiparticulates
EP1560585A1 (en) Dosage form that is safeguarded from abuse
CN101132772B (en) Alcohol resistant dosage forms
WO2014059512A1 (en) Oral drug delivery formulations

Legal Events

Date Code Title Description
AS Assignment

Owner name: PURDUE PHARMA L.P., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EURO-CELTIQUE S.A.;REEL/FRAME:033852/0806

Effective date: 20140926

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION